View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	MEDP
Entity Registrant Name	Medpace Holdings, Inc.
Entity Central Index Key	0001668397
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,484,924
Entity Public Float			$ 182

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 26,485	$ 37,099
Restricted cash	7	308
Accounts receivable and unbilled, net (includes $1.0 million and $2.3 million with related parties at December 31, 2017 and 2016, respectively)	83,079	79,767
Prepaid expenses and other current assets	20,400	16,074
Total current assets	129,971	133,248
Property and equipment, net	48,739	43,805
Goodwill	660,981	660,981
Intangible assets, net	98,740	136,071
Deferred income taxes	6,343	97
Other assets	5,943	4,903
Total assets	950,717	979,105
Current liabilities:
Accounts payable	16,674	10,911
Accrued expenses	23,673	24,417
Pre-funded study costs (includes $1.0 million and $3.9 million with related parties at December 31, 2017 and 2016, respectively)	57,406	51,948
Advanced billings (includes $1.7 million and $7.6 million with related parties at December 31, 2017 and 2016, respectively)	73,756	65,668
Current portion of long-term debt	16,500	12,375
Other current liabilities	4,697	3,284
Total current liabilities	192,706	168,603
Long-term debt, net, less current portion	205,111	151,267
Deemed landlord liability, less current portion	26,602	28,527
Deferred income tax liability	560	12,030
Deferred credit	11,468	0
Other long-term liabilities	10,740	7,968
Total liabilities	447,187	368,395
Commitments and contingencies (see Note 9)	0	0
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2017 and 2016, respectively	0	0
Common stock - $0.01 par-value; 250,000,000 shares authorized at December 31, 2017 and 2016, respectively; 35,466,510 and 40,662,856 shares issued and outstanding at December 31, 2017 and 2016, respectively	355	407
Treasury stock - 200,000 shares at December 31, 2017	(6,030)	0
Additional paid-in capital	630,341	623,629
Accumulated deficit	(120,402)	(9,584)
Accumulated other comprehensive loss	(734)	(3,742)
Total shareholders’ equity	503,530	610,710
Total liabilities and shareholders’ equity	$ 950,717	$ 979,105

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, unbilled services with related parties	$ 1.0	$ 2.3
Pre-funded study costs with related parties	1.0	3.9
Advanced billings with related parties	$ 1.7	$ 7.6
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	250,000,000
Common stock shares issued	35,466,510	40,662,856
Common stock shares outstanding	35,466,510	40,662,856
Treasury stock shares	200,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Service revenue, net (includes $11.1 million, $24.1 million and $24.0 million with related parties for the years ended December 31, 2017, 2016 and 2015, respectively)	$ 386,462	$ 370,621	$ 320,101
Reimbursed out-of-pocket revenue (includes $1.5 million, $5.4 million and $6.9 million with related parties for years ended December 31, 2017, 2016 and 2015, respectively)	49,690	50,961	38,958
Total revenue	436,152	421,582	359,059
Operating expenses:
Direct costs, excluding depreciation and amortization	211,773	198,510	163,707
Reimbursed out-of-pocket expenses (includes $1.5 million, $5.4 million and $6.9 million with related parties for years ended December 31, 2017, 2016 and 2015, respectively)	49,690	50,961	38,958
Selling, general and administrative	63,357	61,507	56,998
Impairment of goodwill	0	0	9,313
Depreciation	8,574	7,442	6,379
Amortization	37,900	50,672	63,142
Total operating expenses	371,294	369,092	338,497
Income from operations	64,858	52,490	20,562
Other expense, net:
Loss on extinguishment of debt	0	(10,726)	0
Miscellaneous expense, net	(354)	(423)	(1,133)
Interest expense, net	(7,559)	(19,384)	(27,259)
Total other expense, net	(7,913)	(30,533)	(28,392)
Income (loss) before income taxes	56,945	21,957	(7,830)
Income tax provision	17,823	8,532	843
Net income (loss)	$ 39,122	$ 13,425	$ (8,673)
Net income (loss) per share attributable to common shareholders:
Basic	$ 1.00	$ 0.38	$ (0.28)
Diluted	$ 0.98	$ 0.37	$ (0.28)
Weighted average common shares outstanding:
Basic	39,056	35,690	31,346
Diluted	39,839	36,329	31,346

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Service revenue with related parties	$ 11.1	$ 24.1	$ 24.0
Reimbursed out-of-pocket revenue with related parties	1.5	5.4	6.9
Reimbursed out-of-pocket expenses with related parties	$ 1.5	$ 5.4	$ 6.9

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 39,122	$ 13,425	$ (8,673)
Other comprehensive loss
Foreign currency translation adjustments, net of taxes	3,008	(1,183)	(999)
Comprehensive income (loss)	$ 42,130	$ 12,242	$ (9,672)

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	AOCI Attributable to Parent
Balance at Dec. 31, 2014	$ 401,970	$ 313		$ 417,553	$ (14,336)	$ (1,560)
Net income (loss)	(8,673)				(8,673)
Issuance of common stock	608	1		607
Foreign currency translation adjustments, net of taxes	(999)					(999)
Stock-based compensation expense	21,127	12		21,115
Stock options exercised	250			250
Tax benefit deficiency from stock-based compensation	(809)			(809)
Balance at Dec. 31, 2015	413,474	326		438,716	(23,009)	(2,559)
Net income (loss)	13,425				13,425
Issuance of common stock	173,578	80		173,498
Foreign currency translation adjustments, net of taxes	(1,183)					(1,183)
Stock-based compensation expense	2,777	1		2,776
Stock options exercised	678			678
Common stock issuance costs	(2,719)			(2,719)
Reclassification of liability classified stock options upon IPO	10,463			10,463
Tax effect of initial public offering related costs	192			192
Tax benefit from stock-based compensation	25			25
Balance at Dec. 31, 2016	610,710	407		623,629	(9,584)	(3,742)
Impact to Retained Earnings from adoption of ASU 2016-09				440	(440)
BALANCE — January 1, 2017	610,710	407		624,069	(10,024)	(3,742)
Net income (loss)	39,122				39,122
Foreign currency translation adjustments, net of taxes	3,008					3,008
Stock-based compensation expense	4,463			4,463
Stock options exercised	1,812	1		1,811
Repurchases of common stock	(149,551)	(51)			(149,500)
Treasury stock purchases	(6,032)	(2)	$ (6,030)
Tax effect of initial public offering related costs	(2)			(2)
Balance at Dec. 31, 2017	$ 503,530	$ 355	$ (6,030)	$ 630,341	$ (120,402)	$ (734)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended					12 Months Ended			24 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 11,291	$ 8,447	$ (21)	$ 3,448		$ 39,122	$ 13,425	$ (8,673)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation						8,574	7,442	6,379
Amortization						37,900	50,672	63,142
Stock-based compensation expense						4,463	9,815	22,324
Amortization of debt issuance costs and discount						662	2,576	2,687
Loss on extinguishment of debt						0	10,726	0
Deferred income tax provision (benefit)						3,237	(9,006)	(12,690)
Impairment of goodwill					$ 9,300	0	0	9,313	$ 0
Amortization and adjustment of deferred credit						(8,781)	0	0
Other						(673)	(1,019)	(242)
Changes in assets and liabilities:
Accounts receivable and unbilled, net						(2,898)	(13,727)	337
Prepaid expenses and other current assets						(3,533)	(3,661)	(181)
Accounts payable						4,816	691	2,481
Accrued expenses						(1,313)	4,516	320
Pre-funded study costs						5,292	5,400	9,981
Advanced billings						7,735	14,723	(7,002)
Other assets and liabilities, net						2,782	(841)	(2,306)
Net cash provided by operating activities						97,385	91,732	85,870
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures						(11,724)	(13,537)	(6,465)
Acquisition of intangibles						(569)	0	0
Other						56	115	33
Net cash used in investing activities						(12,237)	(13,422)	(6,432)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for common stock issuance costs						0	(2,719)	0
Proceeds from stock option exercises						1,812	537	250
Repurchases of common stock						(155,583)	0	0
Excess tax benefit from stock-based compensation						0	25	0
Proceeds from issuance of debt, net of original issue discount						0	164,506	0
Payment of debt						(12,375)	(390,060)	(116,055)
Proceeds from revolving loan						100,000	0	0
Payments on revolving loan						(30,000)	0	0
Debt issuance costs						0	(1,802)	0
Payment of deemed landlord liability						(1,682)	(1,525)	(1,292)
Payment on debt extinguishment						0	(548)	0
Proceeds from common stock issued, net						0	173,578	608
Net cash used in financing activities						(97,828)	(58,008)	(116,489)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH						1,765	(632)	(601)
(DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH						(10,915)	19,670	(37,652)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period		$ 37,407		$ 17,737		37,407	17,737	55,389	17,737
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 26,492		$ 37,407		$ 17,737	26,492	37,407	17,737	$ 26,492
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION—
Cash paid during the period for income taxes						17,180	17,654	10,552
Cash paid during the period for interest						6,888	16,895	24,435
Acquisition of property and equipment—non-cash						$ 678	$ 1,687	$ 176

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	1. BASIS OF PRESENTATION Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Share Repurchases In November 2017, the Board members who are not affiliated with Cinven (the “Disinterested Directors”) approved an agreement to repurchase 2,000,000 shares of the Company’s common stock from Cinven in connection with the Secondary Offering (as described below) for aggregate consideration of approximately $60.3 million, representing a purchase price of $30.16 per share. The Company funded the repurchase with approximately $60.0 million in borrowings under the Senior Secured Revolving Credit Facility and cash on hand. In August 2017, the Disinterested Directors of the Company approved a stock repurchase agreement with Medpace Limited Partnership, a Guernsey limited partnership (the “Limited Partnership” acting through its general partner, Medpace GP Limited, a Guernsey company, the “General Partner” and, the Limited Partnership acting through the General Partner, “Cinven”), pursuant to which the Company repurchased 2,000,000 shares of the Company’s common stock from Cinven for aggregate consideration of approximately $60.5 million, representing a purchase price of $30.27 per share. The Company funded the repurchase with cash on hand and $40.0 million in borrowings under our Senior Secured Revolving Credit Facility. In April 2017, the Board of the Company authorized a share repurchase program with an authorized repurchase level of $50.0 million. The share repurchase program was cancelled in the fourth quarter of 2017. Repurchases under the repurchase program took place in the open market or negotiated transactions, at the discretion of the Company’s management. During the year ended December 31, 2017, the Company repurchased 1,342,786 shares of its outstanding common stock for $34.7 million under this share repurchase program. The Company has elected to constructively retire all repurchased shares with all amounts paid in excess of Common stock par value reflected within Accumulated deficit in the Company’s consolidated balance sheets, except for 200,000 shares, which are reflected within treasury stock in the Company’s consolidated balance sheets. Initial Public Offering On August 11, 2016, the Company's common stock began trading on the NASDAQ Global Select Market (“NASDAQ”) under the symbol "MEDP". On August 16, 2016, the Company completed its initial public offering (“IPO”) of its common stock at a price to the public of $23.00 per share. The Company issued and sold 8,050,000 shares of common stock in the IPO, including 1,050,000 common shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares. The IPO raised net proceeds of approximately $173.6 million after deducting underwriting discounts and commissions. As contemplated in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission on August 11, 2016, the net proceeds from the IPO, along with cash on hand, were used to repay $175.0 million of outstanding borrowings under the 2014 Senior Secured Term Loan Facility (as defined below) and $2.7 million of offering expenses. Secondary Offering During 2017, Cinven sold a total of 4,600,000 shares of the Company’s common stock as part of a secondary offering. The Company incurred professional fees in connection with the secondary offering of $0.4 million during year ended December 31, 2017. The fees are included within operating expenses in the accompanying consolidated statement of operations. As of December 31, 2017, Cinven owned 46.2% of the Company’s outstanding common stock.

Acquisition	12 Months Ended
Acquisition	Dec. 31, 2017
Asset Acquisition [Abstract]
Acquisition	2. ACQUISITION In May 2017, the Company acquired out of bankruptcy NephroGenex, Inc. (“Nephrogenex” or the “Debtor”), a publicly-held pharmaceutical company that had previously filed for relief under Chapter 11 of the United States Bankruptcy Code. The Company, which was the largest unsecured creditor of Nephrogenex, entered into an agreement through the bankruptcy process, to exchange its unsecured claim for 100% of the common stock in the post-bankruptcy, debt-free Debtor. The assets of the acquired Debtor consist primarily of tax attributes as well as in-process research and development and other intangible assets. An analysis by the Company determined that substantially all the fair value of the assets on the date of acquisition is captured in the tax attributes, as the intangible assets account for a relatively immaterial portion of the fair market value of the total assets received. The acquisition of the Debtor was accounted for as an asset purchase. The Company allocated its consideration paid of $1.2 million, consisting of accounts receivable and unbilled receivables and transaction related costs, on a pro rata basis to the assets acquired based on their respective fair values. Acquired assets include intangible assets of $0.5 million, deferred tax assets of $22.2 million, consisting of tax effected net operating losses in the amount of $13.5 million, tax effected capitalized research and development expenses of $8.5 million and tax effected federal tax credits of $0.2 million, and deferred tax liabilities of $0.1 million. The excess amount of fair value received over consideration paid of $21.4 million was recorded as a Deferred credit in the consolidated balance sheets and is recognized within income tax provision in proportion to the realization of the deferred tax assets and federal tax credits prospectively. During the fourth quarter of the year ended December 31, 2017, the Deferred tax assets and related Deferred credit balances were revalued due primarily to the impact of tax reform. See Note 12 of the Notes to Consolidated Financial Statements for further discussion of the impact of tax reform on our consolidated financial statements.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and include the accounts and operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

Significant items that are subject to management estimates and assumptions include service revenue, net, allowances for doubtful accounts, acquisition purchase price allocations, long-lived asset impairment and useful lives, exit liabilities, stock-based compensation, uncertain income tax positions and contingencies.

Reportable Segments

The Company emphasizes its full service outsourcing model, providing services focused on the development, management and execution of clinical trials. As part of this full service approach, the Company utilizes centralized systems, customer interface technology, support functions and processes that cross service offerings and align resources to deliver efficient clinical trial services. Given the full service approach, the chief executive officer, who is the chief operating decision maker (“CODM”) assesses the allocation of resources based on key metrics including revenue, backlog, and net awards by service offering and consolidated profitability and consolidated cash flows. Based on the Company’s full service model, internal management and reporting structure, and key metrics used by the CODM to make resource allocation decisions, management has determined that the Company’s operations consist of a single operating segment. Therefore, results of operations are presented as a single reportable segment.

Foreign Currencies

Assets and liabilities recorded in foreign currencies on foreign subsidiary financial statements are translated at the exchange rate on the balance sheet date, while equity accounts are translated at historical exchange rates. Revenue and expenses are recorded at average rates of exchange during the year. Translation adjustments are recorded to Accumulated other comprehensive loss in the consolidated statements of shareholders’ equity and consolidated statements of comprehensive (loss) income.

Separately, net realized gains and losses on foreign currency transactions are included in Miscellaneous expense, net, on the consolidated statements of operations. Foreign currency transactions resulted in net losses of $1.0 million, $0.7 million and $1.3 million during the years ended December 31, 2017, 2016 and 2015, respectively.

Revenue Recognition

The Company generally enters into contracts with customers to provide services ranging in duration from a few months to several years. The contract terms generally provide for payments based on a fixed fee or unit-of-service arrangement. Revenue on these arrangements is recognized when there is persuasive evidence of an arrangement, the service offering has been delivered to the customer, the arrangement consideration is determinable and the collection of the fees is reasonably assured.

The Company recognizes revenue for services provided on fixed fee arrangements based on the proportional performance methodology, which is determined by assessing the proportion of performance completed or delivered to date compared to total specific measures to be delivered or completed under the terms of the arrangement. The measures utilized to assess performance are specific to the service provided, and the Company generally compares the ratio of hours completed to the total estimated hours necessary to complete the contract. A detailed project budget by hours is developed based on many factors, including but not limited to the scope of the work, the complexity of the study, the participating geographic locations, and the Company’s historical experience. Management believes the reporting and estimation of hours is the best available measure of progress on many of the services provided and best reflects the pattern in which obligations to customers are fulfilled. To assist with the estimation of hours expected to complete a project, regular contract reviews for each project are performed in which performance to date is compared to the most current estimate to complete assumptions. The reviews include an assessment of effort incurred to date compared to expectations based on budget assumptions and other circumstances specific to the project. The total estimated hours necessary to complete a fixed-fee contract, based on these reviews, are updated and any revisions to the existing hours budget result in cumulative adjustments to the amount of revenue recognized in the period in which the revisions are identified.

Fixed-fee contracts provide for pricing modifications upon scope of work changes. The Company recognizes revenue related to work performed in connection with scope changes when the underlying services are performed, a binding contractual commitment has been executed with the customer and collectability is reasonably assured. Costs are not deferred in anticipation of contracts being awarded or amendments being finalized, but are expensed as incurred.

For unit-of-service arrangements, the Company recognizes revenue in the period in which the unit is delivered. Service unit elements largely consist of various project management, consulting and analytical testing services.

Many contractual arrangements combine multiple service elements. For these contracts, arrangement consideration is allocated to identified units of account based on the relative selling price of each unit of account. The best evidence of selling price of a unit of account is vendor specific objective evidence (“VSOE”), which is the price charged when the deliverable is sold separately. When VSOE is not available to determine selling price, management uses relative third party evidence, if available. When neither VSOE nor third party evidence of selling price exists, management uses its best estimate of selling price considering all relevant information that is available.

Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. These contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are agreed upon with the customer and included in Service revenue, net when realization is reasonably assured.

The Company occasionally enters into volume rebate arrangements with customers that provide for rebates if certain specified spending thresholds are met. These rebate obligations are recorded as a reduction of revenue when it appears probable that the customer will earn the rebates and the related amount is estimable. Service revenue is presented net of rebates of $0.2 million, less than $0.1 million and $0.1 million in the consolidated statements of operations during the years ended December 31, 2017, 2016 and 2015, respectively.

The Company records revenue net of any tax assessments by governmental authorities that are imposed and concurrent with specific revenue generating transactions.

Concentration of Credit Risk

Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The cash and cash equivalent balances are held and maintained with financial institutions with reputable credit ratings and, consequently, the Company believes that such funds are subject to minimal credit risk.

The Company generally does not require collateral or other securities to support customer receivables. In the years ended December 31, 2017, 2016 and 2015, credit losses have been immaterial and within management’s expectations. At December 31, 2017 and 2016, there were no customers accounting for more than 10% of the Company’s accounts receivable.

Costs and Expenses

Direct costs, excluding depreciation and amortization, include direct labor and related employee benefits, laboratory supplies, and other expenses contributing to service delivery. Direct costs, excluding depreciation and amortization, are expensed as incurred and are not deferred in anticipation of contracts being awarded or finalization of changes in scope. Selling, general and administrative includes administrative payroll and related employee benefits, sales and marketing expenses, administrative travel, and other expenses not directly related to service delivery. Rent, utilities, supplies, and software license expenses are allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative based on the estimated contribution among service delivery and support function efforts on a percentage basis. Depreciation and amortization is reported separately in the accompanying consolidated statements of operations. Costs of sales and marketing activities not subject to recovery pursuant to customer contracts, such as feasibility assessments and negotiation of contracts, are expensed as incurred and recorded as a component of Selling, general and administrative in the accompanying consolidated statements of operations.

Advertising expenses are recorded as a component of Selling, general and administrative expenses in the accompanying consolidated statements of operations. Total advertising expenses of $0.6 million, $0.6 million and $0.4 million were incurred during the years ended December 31, 2017, 2016 and 2015, respectively.

Reimbursed Out-of-Pocket Expenses

The Company incurs on behalf of its customers various out-of-pocket expenditures including, but not limited to, travel, meetings, printing, and shipping and handling fees, which are reflected as a separate component of operating expenses and recorded in Reimbursed out-of-pocket expenses in the accompanying consolidated statements of operations. Reimbursements received are reflected in Reimbursed out-of-pocket revenue without mark-up or profit in the consolidated statements of operations.

Fees paid to investigators and other disbursements in which the Company acts as an agent on behalf of the customer are recorded net in the consolidated statements of operations with no impact on the Company’s revenue or expenses. Funds received in advance of study expenditures are recorded as Pre-funded study cost liabilities on the consolidated balance sheets. Any pre-funded amounts remaining at the conclusion of a study are returned to the client. Pre-funded study cost disbursements of $138.7 million, $150.3 million and $114.4 million were made during the years ended December 31, 2017, 2016 and 2015, respectively.

Income Taxes

The Company’s consolidated U.S. federal income tax return is comprised of its U.S. subsidiaries and one of its foreign subsidiaries located in Korea. All foreign subsidiaries of the Company file tax returns in their local jurisdictions.

The Company provides for income taxes on all transactions that have been recognized in the consolidated financial statements in accordance with accounting guidance governing income tax accounting. Accordingly, the impact of changes in income tax laws on deferred tax assets and deferred tax liabilities are recognized in net earnings in the period during which such changes are enacted.

The Company records deferred tax assets and liabilities based on temporary differences between the financial statement bases and tax bases of assets and liabilities. Deferred tax assets are recorded for tax benefit carryforwards using tax rates anticipated to be in effect in the year in which the temporary differences are expected to reverse. If it does not appear more likely than not that the full value of a deferred tax asset will be realized, the Company records a valuation allowance against the deferred tax asset, with an offsetting charge to the Company’s income tax provision or benefit. The value of the Company’s deferred tax assets is estimated based on, among other things, the Company’s ability to generate a sufficient level of future taxable income. In estimating future taxable income, the Company has considered both positive and negative evidence, such as historical and forecasted results of operations, and has considered the implementation of prudent and feasible tax planning strategies.

The Company’s current accounting position is that unremitted foreign earnings are indefinitely reinvested. The Company has accrued a provisional Transition Tax on the deemed repatriated earnings that were previously indefinitely reinvested. We will continue to monitor our assertion related to investment of foreign earnings and how this assertion may be impacted by the “Tax Cuts and Jobs Act” (TCJA). See Note 12 for further information regarding how this assertion could be impacted by the TCJA.

The Company follows accounting guidance related to accounting for uncertainty in income taxes which requires significant judgment in determining what constitutes an individual tax position as well as assessing the possible outcome of each tax position. Changes in judgments as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate, and, consequently, the Company’s consolidated financial results. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company determines its liability for uncertain tax positions globally. If the payment of these amounts ultimately proves to be unnecessary, the reversal of liabilities would result in tax benefits being recognized in the period when it is determined the liabilities are no longer necessary. If the calculation of the liability related to uncertain tax positions proves to be more or less than the ultimate assessment, a tax expense or tax benefit would result. Interest and penalties associated with uncertain tax positions are recognized as components of the Company’s Income tax provision.

Research and Development Credits

Research and development credits are available to the Company under tax laws in certain jurisdictions, based on qualifying research and development spend as defined under those tax laws. Certain tax jurisdictions provide refundable credits that are not wholly dependent on the Company’s income tax status or income tax position. In these circumstances the benefit of the credits is recorded as a reduction of operating expense. When they are wholly dependent upon the Company’s income tax position, research and development credits are recognized as a reduction of income tax expense.

Stock-Based Compensation

The Company has stock-based employee compensation plans for which it incurs compensation expense.

Equity Awards

In connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested common shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of our common stock at the date of grant and option terms are not expected to exceed ten years. All outstanding Awards under the 2016 Plan are equity classified awards.

The Company created the 2014 Plan, providing for the future issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock (the “2014 Plan Awards”). The 2014 Plan Awards were subject to either equity or liability-classification pursuant to the terms of the participant’s award agreement and the 2014 Plan based on accounting guidance which governs such transactions.

Stock-based compensation expense for both the 2016 Plan and 2014 Plan is calculated using the fair value method on the grant date. The Company expenses stock-based compensation using a graded vesting schedule.

For liability-classified awards under the 2014 Plan, the Company recorded fair value adjustments up to and including the settlement date. Changes in the fair value of the stock compensation liability that occurred during the requisite service period were recognized as compensation cost over the vesting period. Changes in the fair value of the stock compensation liability that occurred after the end of the requisite service period but before settlement, were compensation cost of the period in which the change occurred.

Stock-based compensation expense is allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations based on the underlying classification and scope of work for the employees receiving the Awards.

Net Income (Loss) Per Share

Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. The Company’s RSAs are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term.

The computation of diluted EPS includes additional common shares, such as unvested RSUs and stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding under the treasury stock method. The treasury stock method assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect.

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 (in thousands, except for earnings per share):



	Year Ended December 31,
	2017		2016		2015
Weighted-average shares:
Common shares outstanding		39,056		35,690		31,346
RSAs		90		88		-
Total weighted-average shares		39,146		35,778		31,346
Earnings per common share—Basic
Net income (loss)	$	39,122	$	13,425	$	(8,673	)
Less: Undistributed earnings allocated to RSAs		90		33		-
Net income (loss) available to common shareholders—Basic	$	39,032	$	13,392	$	(8,673	)

Net income (loss) per common share—Basic	$	1.00	$	0.38	$	(0.28	)

Basic weighted-average common shares outstanding		39,056		35,690		31,346
Effect of diluted shares		783		639		-
Diluted weighted-average shares outstanding		39,839		36,329		31,346

Net income (loss) per common share—Diluted	$	0.98	$	0.37	$	(0.28	)

For the years ended December 31, 2017, 2016 and 2015, the computation of diluted EPS excludes the effect of (in thousands) 0, 0 and 660 combined RSAs and RSUs, and 63, 0 and 1,794 stock options, respectively, due to the Company’s net loss position as well as each respective period’s average fair value of the Company’s common stock not exceeding the exercise prices.

Fair Value Measurements

The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows:

Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities.

Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data.

Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities.

The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses, and advanced billings approximate their carrying amounts due to their short term maturities.

The Company does not have any recurring fair value measurements as of December 31, 2017. There were no transfers between Level 1, Level 2, or Level 3 during the years ended December 31, 2017, 2016 and 2015.

Cash and Cash Equivalents, including Restricted Cash

Cash and cash equivalents, including restricted cash, are invested in demand deposits, all of which have an original maturity of three months or less. Restricted cash consists of customer funds received in advance and subject to specific restrictions, as well as amounts placed in escrow for contingent payments resulting from acquisitions or other contractual arrangements.

Accounts Receivable and Unbilled, Net

Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled services represent service revenue recognized to date that is currently not billable to the customer pursuant to contractual terms. In general, amounts become billable upon the achievement of negotiated contractual events or in accordance with predetermined payment schedules. Amounts classified to unbilled services are those billable to customers within one year from the respective balance sheet date.

The Company grants credit terms to its customers prior to signing a service contract and monitors the creditworthiness of its customers on an ongoing basis. The Company maintains an allowance for doubtful accounts based on specific identification of accounts receivable that are at risk of not being collected. Uncollectible accounts receivable are written off only after all reasonable collection efforts have been exhausted. Moreover, in some cases the Company requires advance payment from its customers for a portion of the study contract price upon the signing of a service contract. These advance payments are deferred and recognized as revenue as services are performed.

Inventory

Inventory, which consists primarily of laboratory supplies, is valued at the lower of cost or market. Inventory is stated at purchased cost using the first-in, first out (FIFO) cost method. The inventory balance is included in Prepaid expenses and other current assets in the consolidated balance sheets.

Property and Equipment

Property and equipment is recorded at cost. Depreciation is provided on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone, and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years for buildings. The Company capitalizes costs of computer software developed for internal use and amortizes these costs on a straight-line basis over the estimated useful life, not to exceed three years. Leasehold improvements and deemed assets from landlord building construction are capitalized and amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term. Repairs and maintenance are expensed as incurred.

Leases

The Company leases facilities and equipment to be used in its operations, some of which require capitalization in accordance with US GAAP. Upon the execution of new leases, the Company determines the appropriate classification of the lease as operating or capital and reflects the impact of this classification in its consolidated financial statements.

Goodwill and Intangible Assets

Goodwill

Goodwill represents the excess of purchase price over the fair value of net assets acquired in business combinations. The carrying value of goodwill is reviewed at least annually for impairment, or as indicators of potential impairment are identified, at the reporting unit level. The reporting units are Phase II-IV clinical research services, Laboratories, and Clinics as of December 31, 2017.

The Company performs its annual impairment tests during the fourth quarter each year, utilizing the quantitative two step model defined by accounting guidance which governs such assessments. The first step involves the Company comparing each of its reporting unit carrying values, inclusive of assigned goodwill, to their respective estimated fair values. Fair value is estimated using a combination of the income approach, a discounted cash flow analysis, and the market approach, utilizing the guideline company method.

If the calculation in the first step results in any of the reporting units’ carrying values exceeding their respective estimated fair values, a second step is performed. The second step requires the Company to allocate the fair value of the reporting unit derived in the first step to the fair value of the reporting unit’s net assets. Any fair value in excess of amounts allocated to such net assets represent the implied fair value of goodwill for that reporting unit. Any excess of reporting unit carrying value of goodwill over the implied fair value of goodwill results in an impairment. There was no indication of impairment related to goodwill based on the fourth quarter 2017 assessment.

Intangible Assets

The Company has an indefinite lived intangible asset related to its trade name. The carrying value of the trade name asset is reviewed at least annually for impairment, or as indicators of potential impairment are identified. The Company performs its annual impairment test in the fourth quarter each year in conjunction with its annual assessment of goodwill. The assessment consists of comparing the carrying value of the indefinite lived intangible asset to its estimated fair value, utilizing the relief from royalty method, an income approach valuation. There was no indication of impairment related to the trade name asset based on the fourth quarter 2017 assessment.

Finite-lived intangible assets consist mainly of the value assigned to customer relationships, backlog and developed technologies. Finite-lived intangible assets are amortized straight-line or using an accelerated method over their estimated useful lives, which range in term from seventeen months to fifteen years.

Impairment of Long-Lived Assets

Long-lived assets, primarily property and equipment and finite-lived intangible assets, are reviewed for impairment and the reasonableness of the estimated useful lives whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable or that a change in useful life may be appropriate. Recoverability for long-lived assets is determined by comparing the forecasted undiscounted cash flows of the operation to which the assets relate to the carrying amount of the assets. If the undiscounted cash flows are less than the carrying amount of the assets, then the Company reduces the carrying value of the assets to estimated fair values, which are primarily based upon forecasted discounted cash flows. Fair value of long-lived assets is determined based on a combination of discounted cash flows and market multiples.

Advanced Billings

Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized.

Deemed Landlord Liabilities

Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties.

Deferred Credit

Deferred credit represents tax credits recognized initially in conjunction with the Nephrogenex asset acquisition that will be recognized within Income tax provision in proportion to the realization of the deferred tax assets and federal tax credits prospectively.

Other Current Liabilities and Other Long-Term Liabilities

Deferred rent represents the cumulative additional portion of rent expense recognized on a straight line basis in conjunction with the Company’s current leases at the balance sheet date. The Company defers incentives received from landlords for the purpose of making leasehold improvements. These liabilities are amortized as a component of rent expense over the term of the respective lease.

Exit liabilities, if any exist, are recorded at their net present value to the extent the Company no longer receives any benefit from the related property and when the Company has ceased all use of the property.

Asset retirement obligations, to the extent they exist, are recorded at their net present value and accreted to the Company’s estimate of liability at the time the obligation would be required to be satisfied.

Recently Adopted Accounting Standards

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-01, Business Combinations. The standard changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Under the new guidance, an entity first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the set is not a business. If it’s not met, the entity then evaluates whether the set meets the requirement that a business include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, and for interim periods within those fiscal years. The Company, as permitted, early adopted ASU 2017-01 using the prospective method in the second quarter of 2017. ASU 2017-01 was considered in the asset acquisition described in Note 2.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting. The new guidance is intended to simplify certain aspects of accounting for share based payments to employees, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The Company elected to adopt this ASU in the first quarter of 2017 as required. The following summarizes the effects of the adoption on the Company's consolidated financial statements:

•

Income taxes - Upon adoption of this standard, all excess tax benefits and tax deficiencies (including tax benefits of dividends, if distributed, on share-based payment awards) are recognized as income tax expense or benefit in the statement of operations. The tax effects of exercised or vested awards are treated as discrete items in the reporting period in which they occur. As a result, the Company recognized discrete adjustments to income tax expense for the year ended December 31, 2017 of less than $0.1 million related to excess tax benefits. The Company also recognizes excess tax benefits regardless of whether the benefit reduces taxes payable in the current period. The Company applied the prospective adoption approach for any unrecognized excess tax benefits beginning in 2017, which did not result in any cumulative-effect adjustment upon adoption. Prior periods have not been adjusted.

•

Forfeitures - Prior to adoption, share-based compensation expense was recognized on a straight line basis, net of estimated forfeitures, such that expense was recognized only for share-based awards that were expected to vest. A forfeiture rate was estimated annually and revised, if necessary, in subsequent periods if actual forfeitures differed from initial estimates. Upon adoption, the Company no longer applies a forfeiture rate and instead accounts for forfeitures as they occur. The Company applied the modified retrospective adoption approach beginning in 2017 and booked an immaterial cumulative-effect adjustment to additional paid-in-capital and retained earnings within Shareholders’ Equity. Prior periods have not been adjusted.

•

Statements of Cash Flows - The Company historically accounted for excess tax benefits on the consolidated statements of cash flows as a financing activity. Upon adoption of this standard, excess tax benefits are classified along with other income tax cash flows as an operating activity. The Company elected to adopt this portion of the standard on a prospective basis beginning in 2017. Prior periods have not been adjusted.

•

Earnings Per Share - The Company uses the treasury stock method to compute diluted earnings per share, unless the effect would be anti-dilutive. Under this method, the Company is no longer required to estimate the tax rate and apply it to the dilutive share calculation for determining the dilutive earnings per share. The Company utilized the prospective adoption approach and applied this methodology beginning in 2017. Prior periods have not been adjusted.

Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's consolidated financial statements or related footnote disclosures.

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The guidance in ASU 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 will be applied on a modified retrospective basis to each prior reporting period presented and is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09 ‘‘Revenue from Contracts with Customers,’’ to clarify the principles of recognizing revenue and create common revenue recognition guidance between US GAAP and International Financial Reporting Standards. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In December 2016, the FASB issued ASU 2016-20 Technical Corrections and Improvements to Topic 606, Revenue From Contracts with Customers. ASUs’ 2016-20, 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-20, 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, deferred the original effective date of ASU 2014-09 by one year. The new standard allows for either a retrospective or modified retrospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017.

The Company continues to evaluate the potential impact of adopting this standard on its business policies, processes and systems, internal control over financial reporting environment, and financial reporting disclosures.

The Company expects that the majority of its contracts will have a single performance obligation that is satisfied over time, with revenue recognized based on overall project progress measured as of the financial statement date. This represents a change in the Company’s current revenue accounting methodology as a majority of contracts are accounted for with multiple units of account under the multiple element arrangement guidance. Under the current accounting methodology, certain revenue related to reimbursable expenses is presented either as a separate line item within Reimbursable out-of-pocket revenue or net of related expenses within Service revenue, net in the consolidated statements of operations. As a result of having a single performance obligation, the Company anticipates that all revenue related to reimbursable expenses will prospectively be accounted for gross within a single revenue line item with related expenses presented gross within Direct Costs, excluding depreciation and amortization. Measurement of progress on contracts with customers will generally be based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The inclusion of reimbursable costs in the measurement of progress under these contracts as part of one performance obligation may create a timing difference between the amounts the Company is entitled to receive in reimbursement for costs incurred and the amount of revenue recognized related to such costs on individual projects.

The Company will adopt ASU 2014-09 as well as the clarified guidance in ASUs’ 2016-20, 2016-12, 2016-10, 2016-08, utilizing the modified retrospective approach, during the first quarter of 2018. The Company is finalizing its assessment and will record a cumulative-effect adjustment to retained earnings upon adoption.

Accounts Receivable And Unbilled, Net

12 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Accounts Receivable And Unbilled, Net

4. ACCOUNTS RECEIVABLE AND UNBILLED, NET

Accounts receivable and unbilled, net includes service revenue and reimbursed out-of-pocket revenue. Accounts receivable and unbilled, net consisted of the following at December 31 (in thousands):


	2017		2016
Accounts receivable	$	55,599	$	48,270
Unbilled	28,153			34,719
Less allowance for doubtful accounts	(673)		(3,222)
Total accounts receivable and unbilled, net	$	83,079	$	79,767

A rollforward of allowance for doubtful account activity is as follows:


	Year Ended December 31,
	2017			2016			2015
Allowance for doubtful accounts - beginning balance	$	(3,222	)	$	(1,724	)	$	(5,855	)
Current year provision		(250	)		(2,166	)		(642	)
Write-offs, recoveries and the effects of foreign currency exchange		2,799			668			4,773
Allowance for doubtful accounts - ending balance	$	(673	)	$	(3,222	)	$	(1,724	)

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Property and Equipment, Net

5. PROPERTY AND EQUIPMENT, NET

Property and equipment, net consisted of the following at December 31 (in thousands):


	2017			2016
Land	$	972		$	543
Equipment		12,171			10,094
Furniture, fixtures, and leasehold improvements		21,280			15,415
Computer hardware, software, and phone equipment		9,571			7,535
Buildings		2,559			2,253
Deemed assets from landlord building construction		22,752			22,752
Construction-in-progress		5,554			2,840
Property and equipment at cost		74,859			61,432
Less: Accumulated depreciation		(26,120	)		(17,627	)
Property and equipment, net	$	48,739		$	43,805

Depreciation expense, which includes amortization from capital leases, was $8.6 million and $7.4 million for the years December 31, 2017 and 2016, respectively.

In 2011, Medpace, Inc. entered into two multi-year lease agreements governing the future occupancy of additional office space in Cincinnati, Ohio. The Company assumed occupancy of both spaces during 2012 and began making lease payments at that time. The leases expire in 2027 and the Company has one 10-year option to extend the term of the leases.

In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase. The accounting guidance requires that a lessee be considered the owner of a real estate project during the construction period if a related party of the lessee is an owner of the real estate. Given that a related party of Medpace made an equity investment in the lessor, Medpace was considered the owner of the property for accounting purposes during the buildings’ construction. Accordingly, the Company reflected the building and related liabilities as Deemed assets from landlord building construction (“Deemed Assets”) and Deemed landlord liabilities, respectively in the consolidated balance sheets. The Deemed Assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease.

Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

6. GOODWILL AND INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill are as follows (in thousands):

Balance as of December 31, 2015	$	660,981
Impairment of Goodwill	-
Balance as of December 31, 2017 and 2016	$	660,981

The annual impairment test performed in the fourth quarter of 2015 resulted in an impairment charge of $9.3 million related to the Company’s Clinics reporting unit. The 2015 goodwill impairment charge represents the total accumulated goodwill impairment losses recognized to date on existing goodwill through December 31, 2017.

Total assets carried on the balance sheet and not remeasured to fair value on a recurring basis, identified as Level 3 measurements, as of December 31, 2017 are $692.6 million, comprised of $661.0 million of goodwill and $31.6 million of identified indefinite-lived intangible assets.

Intangible Assets, Net

Intangible assets, net consisted of the following at December 31 (in thousands):



	2017			2016
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		3,074			2,505
Total finite-lived intangible assets		275,230			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(92,661	)		(66,267	)
Developed technologies		(40,856	)		(29,961	)
Other		(1,989	)		(1,378	)
Total accumulated amortization		(208,136	)		(170,236	)
Total finite-lived intangible assets, net		67,094			104,425
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	98,740		$	136,071

As of December 31, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):


2018	$	29,561
2019		14,829
2020		7,876
2021		5,114
2022		3,353
Later years		6,361
	$	67,094

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Expenses

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Accrued Expenses

7. ACCRUED EXPENSES

Accrued expenses consisted of the following at December 31 (in thousands):


	2017		2016
Employee compensation and benefits	$	19,707	$	21,453
Other		3,966		2,964
Total accrued expenses	$	23,673	$	24,417

Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Debt

8. DEBT

Debt consisted of the following at December 31 (in thousands):



	2017			2016

Revolving credit facility	$	70,000		$	-
Term loan		152,625			165,000
Less unamortized discount		(399	)		(534	)
Less unamortized term loan debt issuance costs		(615	)		(824	)
Less current portion of long-term debt		(16,500	)		(12,375	)
Long-term debt, net, less current portion	$	205,111		$	151,267

Principal payments on debt are due as follows (in thousands):


2018		16,500
2019		16,500
2020		20,625
2021		169,000
Total	$	222,625

The estimated fair value of the Company’s debt based on Level 2 inputs using the market approach, which is primarily based on rates at which the debt is traded among financial institutions, approximates carrying value as of December 31, 2017 and 2016, respectively.

2016 Credit Agreement

On December 8, 2016 (the “Closing Date”), Medpace IntermediateCo, Inc., as borrower (the “Borrower”), and Medpace Acquisition, Inc., a wholly-owned subsidiary of Medpace Holdings, Inc. (the “Company”), as parent guarantor (the “Parent Guarantor”), entered into a credit agreement (the “Senior Secured Credit Agreement”) consisting of a $165.0 million term loan (the “Senior Secured Term Loan Facility”) issued at 99.7% and a $150.0 million revolving credit facility (the “Senior Secured Revolving Credit Facility” and, together with the Senior Secured Term Loan Facility, the “Senior Secured Credit Facilities”). The Senior Secured Term Loan Facility and Senior Secured Revolving Credit Facility expire in December 2021.

The Senior Secured Credit Facilities provide for, at the Company’s option, interest at the Eurocurrency rate or Base rate for the Senior Secured Term Loan Facility and the Senior Secured Revolving Credit Facility borrowings. The Company, at its discretion, may choose interest periods of one, two, three or six months, which determines the interest rate to be applied. Interest on Eurocurrency loans continues to be payable at the end of the selected Eurocurrency term and interest on Base rate loans are payable quarterly in conjunction with any required principal payments.

Borrowings under the Senior Secured Credit Facilities bear interest at a rate equal to, at our option, either (i) the adjusted Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period plus an applicable margin from 1.25% to 2.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00, or (ii) an alternative base rate (determined by reference to the highest of (a) the prime commercial lending rate of the administrative agent, as established from time to time, (b) the Federal Funds Rate plus 0.50% and (c) the one-month adjusted Eurocurrency rate for loans in U.S. dollars plus 1.00%) plus an applicable margin from 0.25% to 1.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00. The applicable margin as of December 31, 2017 was 1.25% for eurocurrency loans and 0.25% for base rate loans. The Company may voluntarily prepay outstanding loans under the Senior Secured Credit Facilities without premium or penalty. As of December 31, 2017, the interest rate applicable on the term loan was the Eurocurrency interest rate of 2.82%.

In addition, the Company is required to pay to the lenders a commitment fee on a quarterly basis at an annual rate of 0.375% of the unused borrowings under the Senior Secured Revolving Credit Facility for the first full fiscal quarter after the closing date, and thereafter 0.50% if the total net leverage ratio is greater than or equal to 3.00:1.00, or 0.375% if the total net leverage ratio is less than 3.00:1.00. At December 31, 2017 and 2016, respectively, the Company had $70.0 million and no outstanding borrowings under the Senior Secured Revolving Credit Facility, resulting in $80.0 million and $150.0 million in undrawn capacity available under the Senior Secured Revolving Credit Facility. As of December 31, 2017, the interest rate applicable on the Senior Secured Revolving Credit Facility was the Eurocurrency interest rate of 2.82%. In addition, the Company had $0.3 million and $0.1 million in letters of credit outstanding, which are secured by the Senior Secured Revolving Credit Facility at December 31, 2017 and 2016.

The original issue discount of $0.5 million related to the issuance of the Senior Secured Term Loan Facility was recorded as a reduction of the underlying debt issuances within Long-term debt, net, less current portion and is being amortized over the life of the debt using the effective-interest method. The unamortized portion of the discount related to the Senior Secured Term Loan Facility was $0.4 million and $0.5 million as of December 31, 2017 and 2016, respectively. Per the terms of the Senior Secured Credit Term Loan Facility, principal is scheduled to be paid quarterly on the last business day of March, June, September and December of each year, beginning March 2017.

Origination fees of $0.8 million related to the Senior Secured Term Loan Facility were recorded as a reduction of the underlying debt issuances in Long-term debt, net. These fees are being amortized over the life of the debt using the effective-interest method. The unamortized portion of the origination fees related to the Senior Secured Term Loan Facility was $0.6 million and $0.8 million at December 31, 2017 and 2016, respectively. Origination fees of $1.6 million related to the Senior Secured Revolving Credit Facility were originally capitalized as a component of Other assets. These fees are being amortized over the life of the debt using the effective-interest method. The unamortized portion of the origination fees related to the Senior Secured Revolving Credit Facility was $1.3 million and $1.6 million at December 31, 2017 and 2016, respectively.

The Senior Secured Credit Facilities are guaranteed by the Parent Guarantor and its material, direct or indirect wholly owned domestic subsidiaries, with certain exceptions, including where providing such guarantees is not permitted by law, regulation or contract or would result in adverse tax consequences. The Senior Secured Credit Facilities are subject to customary covenants relating to financial ratios and restrictions on certain types of transactions, including restricting the Company's ability to incur additional indebtedness, acquire and dispose of assets, make investments, pay dividends, or engage in mergers and acquisitions. The Company is required to maintain a ratio of consolidated funded indebtedness minus unrestricted cash and cash equivalents (in the aggregate not to exceed $50 million and to include not more than $25 million of foreign unrestricted cash and cash equivalents) to consolidated EBITDA for the most recent four fiscal quarter period not to exceed 4.00:1.00; provided that the Company shall be permitted to increase the ratio to 4.50:1.00 in connection with any permitted acquisition or any other acquisition consented to by the Administrative Agent and the Required Lenders (as defined in the Senior Secured Credit Agreement) with total cash consideration in excess of $25 million. Such increase shall be applicable for the fiscal quarter in which such acquisition is consummated and the three consecutive test periods thereafter. The Company is also required to maintain a ratio of consolidated EBITDA to consolidated interest expense, in each case for the most recent four fiscal quarter period, of not less than 3.00:1.00. The Company was in compliance with all financial covenants as of December 31, 2017.

Borrowings under the Senior Secured Credit Facilities were utilized to repay and extinguish our obligations under the 2014 Senior Secured Credit Facilities (as defined below). In accordance with accounting guidance governing such transactions, upon closing the 2014 Senior Secured Credit Facility (as defined below) and commencement of the Senior Secured Credit Facilities, the Company recognized a loss on extinguishment of debt totaling $10.7 million, of which $10.2 million related to unamortized loan origination fees from the credit agreement for our 2014 Senior Secured Credit Facilities (as defined below) and $0.5 million related to third party fees incurred during the fourth quarter of 2016.

2014 Credit Agreement

On April 1, 2014, the Company entered into a credit agreement, consisting of a $530 million term loan (“2014 Senior Secured Term Loan Facility”) and a $60 million revolving credit facility ("2014 Senior Secured Revolving Credit Facility" and together with the 2014 Senior Secured Term Loan Facility, the “2014 Senior Secured Credit Facilities”). The 2014 Senior Secured Term Loan Facility, which was terminated in 2016 in connection with the new borrowings under the Senior Secured Credit Facility, was guaranteed by the Company and its subsidiaries and was subject to customary covenants relating to financial ratios and restrictions on certain types of transactions, including restricting the Company's ability to incur additional indebtedness, acquire and dispose of assets, make investments, pay dividends, or engage in mergers and acquisitions.

Borrowings under the 2014 Senior Secured Credit Facilities incurred interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 3.75% if our total net leverage ratio was less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate was deemed to be no less than 1.00% per annum; (b) a base rate, which was defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 2.75% if our total leverage ratio was less than or equal to 4.75:1.00; provided that the base rate was deemed to be no less than 2.00% per annum. In addition, the Company was required to pay to the lenders a commitment fee of 0.5% quarterly for unused commitments on the 2014 Senior Secured Revolving Credit Facility, subject to a step-down to 0.375% based upon achievement of a certain leverage ratio as defined within the 2014 Senior Secured Credit Facilities. The Company was able to voluntarily prepay outstanding loans under the 2014 Senior Secured Credit Facilities without premium or penalty.

Commitments, Contingencies, and Guarantees

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Commitments, Contingencies, and Guarantees

9. COMMITMENTS, CONTINGENCIES, AND GUARANTEES

Lease Obligations

The Company has payment obligations under non-cancellable operating leases, primarily for office space and furniture and fixtures to support its global operations. These leases often contain customary scheduled rent increases or escalation clauses and renewal options. Rent expense is recorded on a straight line basis. As of December 31, 2017, minimum future lease payments required under these leases are as follows (in thousands):

			Non-Related		Total
	Related Party		Parties Operating		Operating
	Operating Lease		Leases		Leases
2018	$	2,164	$	4,841	$	7,005
2019		2,164		3,052		5,216
2020		2,164		2,459		4,623
2021		2,164		1,979		4,143
2022		1,803		1,709		3,512
Thereafter		-		3,264		3,264
Total minimum lease payments	$	10,459	$	17,304	$	27,763

The related party operating lease is for one of the Company’s three buildings within its corporate headquarters. The non-related party operating leases are for the Company’s remaining leases throughout the world consisting primarily of office space, fixtures and vehicles.

Rental expense under operating leases totaled $7.9 million, $6.7 million and $5.8 million for the years ended December 31, 2017, 2016 and 2015, respectively, and is allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations.

Deemed Landlord Liabilities

As of December 31, 2017, minimum annual payments required in conjunction with the Deemed landlord liabilities are as follows (in thousands):

	Related Party				Total
	Minimum Lease		Less:		Principal
	Payments		Interest		Amounts Due
2018	$	3,852	$	1,960	$	1,892
2019		3,937		1,819		2,118
2020		3,988		1,662		2,326
2021		4,039		1,490		2,549
2022		4,092		1,301		2,791
Thereafter		19,842		3,024		16,818
Total	$	39,750	$	11,256	$	28,494

Legal Proceedings

Medpace periodically becomes involved in various claims and lawsuits that are incidental to its business. Management believes, after consultation with counsel, that no matters currently pending would, in the event of an adverse outcome, have a material impact on the Company’s consolidated balance sheets, statements of operations, or cash flows.

In March 2012, the Company filed a legal claim against one of its customers, citing as a basis for its claim the customer’s non-payment of more than $6.5 million in outstanding invoices. In response, the customer filed a counterclaim against the Company for compensatory damages, asserting that the Company had willfully and wrongly withheld clinical study data alleged to be owned by the customer. The Company objected to these allegations and believed it had meritorious defenses against these claims and also believed that it would ultimately prevail in this matter. During 2015, a Settlement and Mutual Release Agreement (the “Agreement”) was entered into whereas the Company agreed to settle all outstanding claims for payment of $2.0 million from the customer and both parties waived the right to file any future suits. The customer paid the $2.0 million settlement during 2015 and the Company recorded a bad debt recovery of $2.0 million in Selling, general and administrative in the consolidated statements of operations.

Shareholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Shareholders' Equity

10. SHAREHOLDERS’ EQUITY

Authorized Shares

On August 16, 2016 the Company amended its Certificate of Incorporation in connection with the closing of its IPO to increase the authorized number of shares of common stock to 250,000,000 and to authorize 5,000,000 shares of preferred stock that may be issued from time to time by the Company’s Board of Directors.

Stock-Based Compensation

2016 Incentive Award Plan

On August 11, 2016 in connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards, which are all equity-classified instruments under the 2016 Plan. The number of shares registered and available for grant under the 2016 Plan is 6,000,000. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of the Company’s common stock at the date of grant and option terms are not expected to exceed ten years.

The Company granted 1,009,896 awards under the 2016 Plan during the year ended December 31, 2017, consisting of 797,550 stock option awards, 118,000 restricted stock awards (“RSA”) and 38,000 restricted stock units (“RSU”), all vesting after four years. The Company granted an additional 41,346 stock option awards, vesting over one year, to non-employee directors under the 2016 Incentive Award Plan, during the year ended December 31, 2017. Additionally, the Company granted 15,000 stock option awards, vesting equally on the second, third and fourth anniversary of the grant date over four years.

The Company granted 648,180 stock options under the 2016 Plan during the year ended December 31, 2016, consisting of 626,650 stock options vesting after four years and 21,530 stock options with various vesting schedules, but all of which vest within a calendar year of the respective grant date. The 2016 Plan has reserved 6,000,000 shares for issuance of RSAs, RSUs or stock options, of which approximately 4.3 million awards were available for future grants as of December 31, 2017.

The 2016 Plan expires in 2026, except for awards then outstanding, and is administered by the Board. All Awards granted at the IPO or thereafter were or will be issued under the 2016 Plan.

The company satisfies stock option exercises and vested stock awards with newly issued shares. Shares available for future stock compensation grants totaled 4.3 million and 5.4 million at December 31, 2017 and 2016.

2014 Equity Incentive Plan

The 2014 Plan for employees and directors provided the issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock. The awards were granted to key employees as additional compensation for services rendered and as a means of retention over the vesting period, typically three to four years. RSAs awarded under the 2014 Plan were subject to automatic forfeiture upon departure until vested and entitle the shareholder to all rights of common stock ownership except that they may not be sold, transferred, pledged or otherwise disposed of during the restriction period, except as noted in the following paragraph. The 2014 Plan allowed for the issuance of non-qualified stock options to employees, officers, and directors under this plan (collectively, “the Participants”). Under the 2014 Plan, options could be granted with an exercise price equal to or greater than the fair value of common stock at the grant date as determined by the Board of Directors. The stock options, if unexercised, expired seven years from the date of grant. The Company granted 45,932 Awards under the 2014 Plan, consisting of 34,821 stock options vesting equally over four years and 11,111 fully vested shares, during the year ended December 31, 2016.

As a condition to exercising stock options and acceptance of certain restricted shares, employees must have executed a Contribution and Subscription Agreement (the “Subscription Agreement”) that provided for the exchange of the shares issued for incentive units (the “Incentive Units”) in Medpace Investors upon the occurrence of certain events. The Incentive Units were tied directly to common stock ownership in Medpace Holdings, Inc. and entitled the Incentive Unit holder to participate in the risks and rewards of owning the Company’s stock through ownership in Medpace Investors. The awards containing this condition were liability-classified instruments as they were inevitably settled in the equity of a non-consolidated related party. Restricted share awards excluding the requirement to execute a Contribution and Subscription Agreement and settlement in common shares of Medpace Holdings, Inc. were equity-classified instruments.

At the grant date for RSAs that were liability-classified, restricted shares were legally issued and exchanged for MPI Incentive Units on behalf of the employee. If the RSAs were not yet vested and an employee left the Company’s employment, the restricted shares of Medpace Holdings, Inc. reverted back to the Company and were available for re-issuance under the 2014 Plan. Upon the vesting of RSAs and RSUs and upon the exercise of stock options, the stock-based compensation liability was settled by exchanging the Company’s stock for MPI Incentive Units. If an employee left the Company’s employment after they vested in the Awards and the exchange for Incentive Units was made, Medpace Investors may exercise a call option to repurchase an employee’s Incentive Units at a price determined by the manager and majority unit holder of Medpace Investors, who is also the chief executive officer of Medpace. If Medpace Investors exercised the call right, it could do so up to the later of twelve months following the employee’s departure date or six months following the determination that the former employee was directly or indirectly engaged in competitive business activities.

Restricted Awards Modification

On December 17, 2015, the Board of Directors approved a resolution to accelerate the vesting period for all issued, outstanding and unvested RSAs and RSUs to vest on December 31, 2015, so long as the recipient of each restricted share or unit was in good standing, had not provided notice of resignation and continued to be employed by the Company as of December 31, 2015. In total, 688,599 unvested restricted awards held by 158 current employees were modified resulting in settlement of 688,599 shares.

According to the authoritative guidance for stock-based compensation, under these circumstances a company should recognize additional stock-based compensation expense in the amount of the incremental fair value of the modified award. Because the restricted awards that were modified were liability-classified, the awards were at fair value at the time of the modification and no incremental cost was recognized. While there was no incremental cost related to fair value of the awards, $5.7 million of stock-based compensation expense was recorded in 2015 related to previously unrecognized stock-based compensation cost for awards expected to vest in 2016, 2017 and 2018.

Option Awards Modification

As a result of the Company’s IPO, a condition of all outstanding stock options issued before August 10, 2016 under the 2014 Plan that previously required the exchange of the shares issued for incentive units in the equity of a non-consolidated related party was dissolved. All future exercises of options issued pursuant to the 2014 Plan will now settle in shares of the Company. As a result of the modification in the settlement condition, the options will now be equity-classified instruments and changes in the fair value of the stock compensation liability that occur during the requisite service period are no longer recognized. According to the authoritative guidance for stock-based compensation, at modification the Company should recognize additional stock-based compensation expense in the amount of the incremental fair value of the modified award. As a result, the Company recognized $3.1 million of incremental stock-based compensation expense during the year ended December 31, 2016. In addition, the $10.5 million stock-based compensation liability associated with the modified stock options was reclassified to additional paid-in capital as a result of the change to equity classification. There is no stock-based compensation liability for the years ended December 31, 2017 and 2016.

Equity Awards

Valuation Assumptions

The Company determines the fair value of stock options using the Black-Scholes-Merten option pricing model (the “BSM Model”). The BSM Model is primarily affected by the fair value of the Company’s common stock (see restricted share valuation discussion below), the expected holding period for the option, expected stock price volatility over the term of the awards, the risk-free interest rate, and expected dividends.

The following table sets forth the key weighted-average assumptions used in the BSM Model to calculate the fair value of options:



	Year Ended December 31,
	2017		2016		2015
Expected holding period - years	5.4		3.6		4.2
Expected volatility	28.0%			30.2%		36.4%
Risk-free interest rate	2.0%			1.0%		1.2%
Expected dividend yield		0.0%		0.0%		0.0%

The assumptions used in the table above reflect both grant date inputs to arrive at the grant date fair values for stock options subject to equity-classified stock compensation accounting and reflect a fair value calculation for stock options outstanding in the period subject to liability-classified stock compensation accounting. Subsequent to August 10, 2016, all outstanding stock based awards are subject to equity classification through either modifications of the award terms and conditions that occurred during the years ended December 31, 2016 and 2015, or based on terms and conditions applicable as of the grant date.

The expected holding period represents the period of time the grants are expected to be outstanding. The Company uses the simplified method, as prescribed by accounting guidance governing such awards, to calculate the expected holding period for options granted to employees as we do not have sufficient historical evidence data to provide a reasonable basis upon which to estimate the expected holding period. For options valued by the Company for the years ended December 31, 2017, 2016 and 2015, the expected holding period is based on an average between the midpoint of the vesting date and the expiration date of the options.

The Company estimates expected volatility primarily by using the historical volatility of a publicly traded peer group that operates in the clinical research and development industry. The Company does not have adequate history to calculate its own historical or implied volatility and believes the Company’s expected volatility will approximate the historical experience of the peer group.

The risk-free interest rate is based on the yield on U.S. Treasury obligations with remaining durations equal to the expected holding period of the options. The expected dividend yield is assumed to be zero based on recent and anticipated dividend activity.

Subsequent to the IPO, the fair value of common stock is based upon the market price of the Company’s common stock on the date of grant as listed on the NASDAQ. Due to the absence of an active market for the Company’s common stock prior to the IPO, the Company determined the fair value of restricted shares by obtaining an independent valuation of the fair value of the Company’s equity, applying a discount for lack of marketability, and then calculating the implied share price. The fair value of the Company was estimated primarily using an income approach which is based on assumptions and estimates made by management and, secondarily, using other market-related factors in current industry trends as well as observed transaction values. In determining the estimated future cash flows used in the income approach, the Company developed and applied certain estimates and judgments, including current and projected future levels of income based on management’s plans, business trends, prospects and market and economic conditions, including market-participant considerations. Significant assumptions utilized in the income approach were based on company specific information and projections, which were not observable in the market and are thus considered Level 3 measurements by authoritative guidance. The discount for lack of marketability (the “Marketability Discount”) was applied to reflect what a market participant would consider in relation to the post-vesting restrictions imposed regarding the inability to sell, transfer, or pledge the shares during the restriction period. The Marketability Discount was estimated by using the BSM Model to calculate the cost of a theoretical put option to hedge the fluctuation in value of the investment between the valuation date and an anticipated liquidity date.

The following table summarizes the grant date fair values of stock options and restricted shares issued during the period as well as the allocation of stock-based compensation expense to Direct costs, excluding depreciation and amortization, and Selling, general and administrative reported in the consolidated statements of operations:



	Year Ended December 31,
	2017		2016		2015
Weighted average, grant date fair value
Stock Options	$	8.54	$	6.91	$	3.81
Restricted shares (RSAs and RSUs)	$	31.90	$	15.08	$	12.53

Stock-based compensation expense allocated to:
Direct costs, excluding depreciation and amortization	$	2,128	$	5,555	$	9,243
Selling, general, and administrative		2,335		4,260		13,081
Total stock-based compensation expense	$	4,463	$	9,815	$	22,324

Award Activity

The following table sets forth the Company’s stock option activity:


	Year Ended December 31,
	2017					2016					2015
				Weighted Average					Weighted Average					Weighted Average
	Options			Exercise Price		Options			Exercise Price		Shares			Exercise Price
Outstanding - beginning of Period		2,350,166		$	17.57		1,794,709		$	15.42		1,091,048		$	14.40
Granted		853,896		$	28.67		683,001		$	22.80		889,849		$	16.67
Exercised		(116,787	)	$	15.52		(36,980	)	$	14.50		(17,404	)	$	14.41
Forfeited/Expired		(304,407	)	$	20.55		(90,564	)	$	15.85		(168,784	)	$	15.53
Outstanding - end of period		2,782,868		$	20.73		2,350,166		$	17.57		1,794,709		$	15.42

Exercisable - end of period		917,592		$	15.40		647,343		$	15.22		242,777		$	14.40

The following table sets forth the Company’s Restricted Share activity:



	Year Ended December 31,
	2017			2016			2015
	Shares			Shares			Shares
Outstanding and unvested - beginning of period		59,258			90,697			407,171
Granted		156,000			11,111			1,253,924
Vested		(29,629	)		(41,069	)		(1,530,547	)
Forfeited		(2,000	)		(1,481	)		(39,851	)
Outstanding and unvested - end of period		183,629			59,258			90,697

Cumulative vested shares - end of period		1,884,287			1,854,658			1,813,589

During the years ended December 31, 2017, 2016 and 2015, 0, 11,111 and 583,021 Restricted Shares were granted and immediately vested upon issuance (the “Vested Shares”), respectively. There was no stock-based compensation liability related to Restricted Shares as of the year ended December 31, 2017 and 2016. The stock-based compensation liability related to 231,229 Vested Shares granted during the year ended December 31, 2015 was settled by exchanging the awards for Medpace Investors’ Incentive Units. The stock-based liability related to the residual 351,851 Vested Shares granted during the year ended December 31, 2015 was settled by exchanging the awards for the Company’s common stock.

The following table summarizes information about stock options expected to vest, stock options exercisable, and unvested restricted share awards expected to vest at December 31, 2017:

	Weighted Average						Weighted Average
	Exercise		Stock		Restricted		Remaining
	Price		Options		Shares		Life (Years)
December 31, 2017
Number of stock options expected to vest	$	20.73		2,782,868		-		4.9
Number of Restricted Shares expected to vest				-		183,629
Total expected to vest - December 31, 2017				2,782,868		183,629
Total stock options exercisable - December 31, 2017	$	15.40		917,592				3.8
Unrecognized compensation cost - December 31, 2017 (in thousands)			$	8,833	$	4,745
Weighted average years over which unrecognized compensation cost will be recognized				1.9		3.3

The following table sets forth the aggregate intrinsic value of stock options exercised, the fair values of awards vested, and share based liabilities settled during the respective periods (in thousands):



	Year Ended December 31,
	2017		2016		2015
Total intrinsic value of stock options exercised	$	1,619	$	403	$	(36	)
Total grant-date fair value of stock options vested	$	1,317	$	1,384	$	1,168
Total grant-date fair value of restricted shares vested	$	447	$	614	$	18,284
Total settlement date fair value of restricted shares vested	$	1,074	$	1,236	$	21,134
Total share-based liabilities settled	$	-	$	76	$	16,858

The actual tax benefits recognized related to stock-based compensation totaled $0.5 million, $1.0 million and $4.6 million for the years ended December 31, 2017, 2016 and 2015, respectively.

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2017
Compensation Related Costs [Abstract]
Employee Benefit Plans	11. EMPLOYEE BENEFIT PLANS The Company provides a 401(k) plan that covers substantially all U.S. employees. Participants can elect to contribute up to 50% of their eligible earnings on a pre-tax basis, subject to Internal Revenue Service annual limitations. The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $2.3 million, $2.0 million and $1.7 million during the years ended December 31, 2017, 2016 and 2015, respectively, and were allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $0.9 million, $0.7 million and $0.7 million in the years ended December 31, 2017, 2016 and 2015, respectively, and were allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. The Company is also required to pay certain minimum statutory post-employment benefits. The Company recognizes a liability and the associated expense for these benefits when it is probable that employees are entitled to the benefit.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

12. INCOME TAXES

US Tax Reform

The “Tax Cuts and Jobs Act” (TCJA) was enacted on December 22, 2017 and it significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, includes a reduction in the U.S. federal tax rate from 35% to 21%, allows for the expensing of capital expenditures, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, creates new taxes on certain foreign sourced earnings and puts into effect the migration from a “worldwide” system of taxation to a territorial system.

The Company has not completed its accounting for the income tax effects of the TCJA. Where the Company has been able to make reasonable estimates of the effects for which its analysis is not yet complete, the Company has recorded provisional amounts in accordance with SEC Staff Accounting Bulletin No. 118. Where the Company has not yet been able to make reasonable estimates of the impact of certain elements, the Company has not recorded any amounts related to those elements and has continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the TCJA.

The Company's accounting for the following elements of the TCJA is incomplete. However, the Company was able to make reasonable estimates of certain effects and, therefore, has recorded provisional amounts as follows:

•

Revaluation of the Deferred Credit, deferred tax assets and liabilities and other miscellaneous tax attributes: The TCJA reduces the U.S. federal corporate tax rate from 35% to 21% for tax years beginning after December 31, 2017. In addition, the TCJA makes certain changes to the depreciation rules and implements new limits on the deductibility of certain executive compensation. The Company has evaluated these changes and has recorded a provisional tax benefit of $3.4 million. The Company is still completing its calculation of the impact of these changes on its deferred tax balances.

•

Transition tax on unrepatriated foreign earnings: The Transition Tax on unrepatriated foreign earnings is a tax on previously untaxed accumulated and current earnings and profits ("E&P") of the Company's foreign subsidiaries. To determine the amount of the Transition Tax, the Company must determine, among other factors, the amount of post-1986 E&P of its foreign subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company was able to make a reasonable estimate of the Transition Tax and has recorded a provisional Transition Tax expense of $0.6 million. The Company is continuing to gather additional information to more precisely compute the amount of the Transition Tax to complete its calculation of E&P as well as the final determination of non-U.S. income taxes paid.

The Company's accounting for the following elements of the TCJA is incomplete, and it has not yet been able to make reasonable estimates of the effects of these items. Therefore, no provisional amounts were recorded.

•

Indefinite reinvestment assertion: Beginning in 2018, the TCJA provides a 100% deduction for dividends received from 10-percent owned foreign corporations by U.S. corporate shareholders, subject to a one-year holding period. Although dividend income is now exempt from U.S. federal tax in the hands of the U.S. corporate shareholders, companies must still apply the guidance of ASC 740-30-25-18 to account for the tax consequences of outside basis differences and other tax impacts of their investments in non-U.S. subsidiaries. The Company has accrued the Transition Tax on the deemed repatriated earnings that were previously indefinitely reinvested. The Company is still evaluating the impacts of the TCJA related to its remaining outside basis differences and how the TCJA will affect the Company's current accounting position to indefinitely reinvest unremitted foreign earnings. The Company expects to finalize its conclusion related to its indefinite reinvestment assertion during the measurement period.

•

Global intangible low taxed income (GILTI): The TCJA creates a new requirement that certain income (i.e., GILTI) earned by foreign subsidiaries must be included currently in the gross income of the U.S. shareholder. Due to the complexity of the new GILTI tax rules, the Company is continuing to evaluate this provision of the TCJA and the application of ASC 740. Under U.S. GAAP, the Company is permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into the Company's measurement of its deferred taxes. The Company has not yet completed its analysis of the GILTI tax rules and is not yet able to reasonably estimate the effect of this provision of the TCJA or make an accounting policy election for the ASC 740 treatment of the GILTI tax. Therefore, the Company has not recorded any amounts related to potential GILTI tax in its financial statements and has not yet made a policy decision regarding whether to record deferred taxes on GILTI.

The Company files income tax returns for U.S. federal and various U.S. states, as well as various foreign jurisdictions. The liabilities for unrecognized tax benefits are carried in Other long-term liabilities on the consolidated balance sheets because the payment of cash is not anticipated within one year of the balance sheet date.

The components of income (loss) before income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017		2016		2015
Domestic	$	52,986	$	18,016	$	(12,294	)
Foreign jurisdictions	$	3,959	$	3,941	$	4,464
Income (loss) before income taxes	$	56,945	$	21,957	$	(7,830	)

Income tax provision (benefit) consisted of the following (in thousands):

	Current		Deferred			Total
Year ended December 31, 2017
U.S. Federal	$	10,953	$	3,466		$	14,419
U.S. state and local		2,032		51			2,083
Foreign jurisdictions		1,576		(255	)		1,321
	$	14,561	$	3,262		$	17,823

Year ended December 31, 2016
U.S. Federal	$	15,105	$	(8,784	)	$	6,321
U.S. state and local		1,636		(524	)		1,112
Foreign jurisdictions		710		389			1,099
	$	17,451	$	(8,919	)	$	8,532

Year ended December 31, 2015
U.S. Federal	$	11,067	$	(11,995	)	$	(928	)
U.S. state and local		1,119		(761	)		358
Foreign jurisdictions		1,372		41			1,413
	$	13,558	$	(12,715	)	$	843

The difference between the statutory rate for federal income tax and the effective income tax rate was as follows (in thousands):



	Year Ended December 31,
	2017					2016					2015
Income tax expense calculated at the federal statutory rate	$	19,931		35.0	%	$	7,685		35.0	%	$	(2,740	)		35.0	%
Effect of:
State and local taxes, net of federal benefit		1,606		2.8			912		4.2			487			(6.2	)
Tax on foreign earnings, net of tax credits and deductions		(69	)	(0.1	)		(26	)	(0.1	)		(330	)		4.2
Tax reform adjustment		(3,418	)	(6.0	)
Deferred credit		(1,053	)	(1.9	)
Change in valuation allowance		-		-			-		-			-			-
Permanent items:
Goodwill impairment		-		-			-		-			2,106			(26.9	)
Stock-based awards		(179	)	(0.3	)		(534	)	(2.4	)		778			(9.9	)
Tax reform adjustment		574		1.0			-		-			-			-
Other		483		0.9			174		0.8			185			(2.4	)
State/Local tax credits		(1,187	)	(2.1	)		(1,049	)	(4.8	)		(931	)		11.9
Change in liability for uncertain tax positions		1,141		2.0			1,212		5.5			1,250			(16.0	)
Other		(6	)	(0.0	)		158		0.7			38			(0.5	)
	$	17,823		31.3	%	$	8,532		38.9	%	$	843		(10.8)%

Components of the Company’s net deferred tax asset (liability) included in the consolidated balance sheets consisted of the following at December 31 (in thousands):


	2017			2016
Deferred tax assets:
Accrued liabilities	$	17,563		$	19,393
Depreciation and amortization		980			1,787
Foreign operating loss carryforward		246			246
U.S. federal tax credits and carryforward		8,152			-
U.S. state and local tax credits and carryforward		1,799			385
Other		667			1,209
Valuation allowance		(2,394	)		(987	)
Total deferred tax assets		27,013			22,033

Deferred tax liabilities:
Depreciation and amortization		(20,117	)		(33,436	)
Prepaid expenses		(572	)		(310	)
Other		(541	)		(220	)
Total deferred tax liabilities		(21,230	)		(33,966	)
Net deferred tax asset (liability)	$	5,783		$	(11,933	)

The deferred tax asset attributable to U.S federal tax credits and carryforwards includes $8.0 million of U.S. federal operating loss carryforwards that will expire at various times from 2031 to 2037 if not utilized. U.S. state and local tax credits and carryforwards above includes $1.3 million for U.S. state and local operating loss carryforwards that will expire at various times from 2026 to 2032 if not utilized.

The Company has foreign operating loss carryforwards for which a deferred tax asset of $0.2 million has been established. The Company has a valuation allowance of $0.2 million against this deferred tax asset based upon its assessment that it is more likely than not that this amount will not be realized. The ultimate realization of this tax benefit is dependent upon the generation of sufficient operating income in the respective tax jurisdictions. Approximately 74% of the foreign net operating loss carryforwards can be utilized over an indefinite period whereas the remainder will expire at various times from 2020 to 2025 if not utilized.

In May 2017, the Company acquired Nephrogenex which included deferred tax assets of $22.2 million, consisting of tax effected net operating losses in the amount of $13.5 million, tax effected capitalized research and development expenses of $8.5 million and tax effected federal tax credits of $0.2 million, and deferred tax liabilities of $0.1 million. See Note 2 for further description of the asset acquisition that occurred in the second quarter of 2017.

Annual activity related to the Company’s valuation allowance is as follows (in thousands):



	Year Ended December 31,
	2017			2016			2015
Beginning Balance	$	987		$	1,021		$	1,086
Additions charged to expense		-			-			-
Additions due to asset acquisition		2,033			-			-
Reductions from utilization, reassessments and expirations		3			(34	)		(65	)
Remeasurement due to effect of tax reform		(629	)		-			-
Ending Balance	$	2,394		$	987		$	1,021

A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2017		2016			2015
Beginning Balance	$	5,698	$	2,604		$	1,353
Increases in tax positions for prior years		5		-			-
Decreases in tax positions for prior years		-		(196	)		(14	)
Increases in tax positions for current year		1,187		3,365			1,265
Lapse in statute of limitations		-		(75	)		-
Ending Balance	$	6,890	$	5,698		$	2,604

Interest and penalties associated with uncertain tax positions are recognized as components of Income tax provision in the consolidated statements of operations. There was no material change to tax-related interest and penalties during the years ended December 31, 2017, 2016 and 2015. As of December 31, 2017 and 2016, respectively, the Company has a liability for interest and penalties of $1.4 million and $1.0 million that is associated with related tax liabilities of $5.9 million and $4.3 million for uncertain tax positions.

The Company operates in various foreign, state and local jurisdictions. The number of tax years for which the statute of limitations remains open for foreign, state and local jurisdictions varies by jurisdiction and is approximately four years (2013 through 2017). For federal tax purposes, the Company’s open tax years are 2014 through 2017.

Miscellaneous Expense, Net

12 Months Ended

Dec. 31, 2017

Other Income And Expenses [Abstract]

Miscellaneous Expense, Net

13. MISCELLANEOUS EXPENSE, NET

Miscellaneous expense, net consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016			2015
Net loss on foreign-currency transactions	$	(1,004	)	$	(660	)	$	(1,307	)
Other income		650			237			174
Miscellaneous expense, net	$	(354	)	$	(423	)	$	(1,133	)

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	14. RELATED PARTY TRANSACTIONS Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $0.2 million existed at December 31, 2017 and 2016, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the consolidated balance sheets, respectively, depending on the contractual repayment date. Management Fees In conjunction with the IPO, the Advisory Services Agreement with Cinven Capital Management (V) General Partner Limited (“Cinven”) expired. Subsequent to the IPO, the Company pays fees for director services provided by Cinven employees that are members of the Company’s Board of Directors and any related committees. The director fees are paid directly to Cinven in accordance with the Company’s non-employee director compensation policy. During the years ended December 31, 2016 and 2015, the Company incurred management fees to Cinven of $0.2 million and $0.3 million, respectively. During the years ended December 31, 2017 and 2016, the Company incurred director fees of $0.1 million, respectively. In connection with these fees, Cinven incurred related travel expenses of $0.1 million, respectively, during the years ended December 31, 2017, 2016 and 2015. As of December 31, 2017 and 2016, the Company had outstanding accounts payable to Cinven of less than $0.1 million and $0.1 million, respectively. Service Agreements Symplmed Pharmaceuticals, LLC (“Symplmed”) Medpace Investors LLC, a noncontrolling shareholder of the Company that is owned by employees of the Company and managed by our chief executive officer, has a majority ownership interest in Symplmed Pharmaceuticals, LLC (“Symplmed”), a private pharmaceutical development company. In addition, the chief executive officer and other executives of the Company are board members of Symplmed. The Company has operated under a Master Services Agreement (“MSA”) with Symplmed since 2013 (amended in 2014) to perform clinical trial related services. Certain task orders governed by this arrangement were amended in the third quarter of 2016, changing the fee structure from unitized in nature to time and materials and revised pricing based on the Company’s leveraging of this work to develop and enhance certain new service capabilities. The Company has evaluated its relationship with Symplmed and concluded that Symplmed is not a variable interest entity because the Company has no direct ownership interest or relationship other than the MSA. During the years ended December 31, 2017, 2016 and 2015, the Company recognized related party transactions of less than $0.1 million, less than $(0.1) million and $1.2 million as service revenue in the consolidated statements of operations, respectively. Coherus BioSciences, Inc. (“Coherus”) and MX II Associates, LLC (“MXII”) The chief executive officer of the Company is a member of Coherus BioSciences, Inc.’s (“Coherus”) board of directors. During 2011 a related party of the Company in which the Company’s chief executive officer is the managing member, MXII, made an investment in Coherus. In early 2012 the Company made a $2.5 million investment in Coherus. Concurrent with the initial investment, MXII secured the exclusive rights for Medpace to perform Phase I through Phase III clinical trial work for certain Coherus’ “bio-similar” drug compounds executed through a MSA. In return, Medpace agreed to pay a 10% sales commission to MXII on cash received from Coherus. The commission agreement between the Company and MXII was terminated during 2015 but did not impact the MSA between the Company and Coherus. The agreement provides for a minimum fee commitment for clinical trial services and is cancelable without cause by either party upon 30 days prior notice. Medpace paid commissions of $1.1 million during the year ended December 31, 2015, which was recorded in Selling, general and administrative in the consolidated statements of operations. During the years ended December 31, 2017, 2016 and 2015, the Company recognized service revenue of $8.0 million, $22.3 million and $22.1 million from Coherus in the Company’s consolidated statements of operations, respectively. In addition, the company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Coherus in the consolidated statements of operations of $1.3 million, $5.1 million and $6.9 million during the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017 and 2016, the Company had Accounts receivable and unbilled, net from Coherus of $0.3 million and $2.0 million recorded in the consolidated balance sheets, respectively. In addition, the Company had Advanced billings of $1.5 million and $6.3 million and Pre-funded study costs of $1.0 million and $3.8 million with Coherus recorded in the consolidated balance sheets at December 31, 2017 and 2016, respectively. Xenon Pharmaceuticals, Inc. (“Xenon”) Certain executives and employees of the Company, including the chief executive officer, have held equity investments in Xenon, a clinical-stage biopharmaceutical company. In addition, a Medpace employee was a director of Xenon until May 2015. During the second quarter of 2017, the chief executive officer sold his entire equity position held in Xenon. Xenon is no longer considered to be a related party subsequent to this sale. During July 2015 the Company and Xenon entered into an amended MSA agreement for the Company to provide clinical trial related services. The Company recognized service revenue from Xenon of $0.6 million, $1.3 million and $0.7 million during the six months ended June 30, 2017 and the years ended December 31, 2016 and 2015, respectively, in the Company’s consolidated statements of operations. In addition, the Company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Xenon in the consolidated statements of operations of $0.1 million, $0.2 million and less than $0.1 million during the six months ended June 30, 2017 and the years ended December 31, 2016 and 2015, respectively. As of December 31, 2016, the Company had Accounts receivable and unbilled, net from Xenon of $0.3 million recorded in the consolidated balance sheets. As of December 31, 2016, the Company had, from Xenon, $1.3 million of Advanced billings and $0.1 million of Pre-funded study costs, in the consolidated balance sheets. Cymabay Therapeutics, Inc. (“Cymabay”) Cymabay is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. During the first quarter of 2016, it was announced that a Medpace employee would join Cymabay’s board of directors. The Company and Cymabay entered into a MSA dated October 21, 2016. Subsequently, the Company and Cymabay have entered into several task orders for the Company to perform clinical trial related services. The Company recognized service revenue from Cymabay of $0.6 million, $0.3 million and $0.1 million during the years ended December 31, 2017, 2016 and 2015, respectively, in the Company’s consolidated statements of operations. As of December 31, 2017 and 2016, the Company had Accounts receivable and unbilled, net from Cymabay of $0.1 million and less than $0.1 million recorded in the consolidated balance sheets, respectively. LIB Therapeutics LLC (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of managers and/or have equity investments in LIB. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform clinical trial related services. The Company recognized service revenue from LIB of $1.4 million and $0.2 million during the years ended December 31, 2017 and 2016 in the Company’s consolidated statements of operations, respectively. As of December 31, 2017 and 2016, the Company had, from LIB, Advanced billings of $0.2 million and less than $0.1 million in the consolidated balance sheets, respectively. In addition, the Company had Accounts receivable and unbilled, net from LIB of $0.5 million and less than $0.1 million in the consolidated balance sheets at December 31, 2017 and 2016, respectively. CinRX Pharma (“CinRx”) Certain executives and employees of the Company, including the chief executive officer, are members of CinRx’s board of managers and/or have equity investments in CinRx, a biotech company. The Company and CinRx have entered into several task orders for the Company to perform clinical trial related services. During the year ended December 31, 2017, the Company recognized service revenue from CinRx of $0.4 million in the Company’s consolidated statements of operations. Medpace Investors, LLC Medpace Investors is a noncontrolling shareholder and related party of Medpace Holdings, Inc. Medpace Investors is owned and managed by employees of the Company. The Company’s chief executive officer is also the manager and majority unit holder of Medpace Investors. The Company acts as a paying agent for Medpace Investors with taxing authorities principally in instances when employee tax payments or remittance of withholdings related to equity compensation are required. During the years ended December 31, 2016 and 2015, the Company paid $0.8 million and $0.9 million to various taxing authorities on behalf of Medpace Investors. During the year ended December 31, 2016, the Company received $0.3 million from Medpace Investors for receivables owed to the Company from Symplmed. Additionally, the Company paid approximately $0.3 million to Medpace Investors due to the settlement of certain liabilities related to the Merger Agreement between the sellers (led by CCMP) and the buyers (led by Cinven). Purchase of Real Estate Properties In December 2016, the Company entered into a purchase agreement for four parcels of real estate property that are closely situated to the Medpace campus in Cincinnati, Ohio, from AT Redevelopment Company, LLC, which is wholly-owned by the Company’s chief executive officer. The purchase price of the real estate property was $0.4 million as determined by an independent third party broker's opinion of value. The transaction closed on January 11, 2017. Leased Real Estate Headquarters Lease The Company has entered into operating leases for its corporate headquarters and a storage space facility with an entity that is wholly owned by the Company’s chief executive officer. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease for headquarters is for an initial term of twelve years through November 2022 with a renewal option for one 10-year term at prevailing market rates. The lease for storage space was through June 2016 and was leased on a month to month basis, thereafter. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters is $2.1 million and allows for adjustments to the rental rate annually for increases in the consumer price index. Lease expense recognized for the years ended December 31, 2017, 2016 and 2015 was $2.1 million, respectively. The lease expense was allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. Deemed Assets and Deemed Landlord Liabilities The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase and at completion. Accordingly, the Company reflected the buildings and related liabilities as deemed assets from landlord building construction in Property and equipment, net, Other current liabilities, and Deemed landlord liabilities, respectively, on the consolidated balance sheets. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10-year option to extend the lease term. The deemed assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease. Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties. Accretion expense is being recorded over the term of the lease as a component of Interest expense, net in the Company’s consolidated statements of operations. The Company paid $3.8 million, $3.7 million and $3.4 million during the years ended December 31, 2017, 2016 and 2015, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2017 were $1.9 million and $26.6 million, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2016 were $1.7 million and $28.5 million, respectively. The Company has recognized $16.3 million and $18.1 million, respectively, of deemed assets, net at December 31, 2017 and 2016 in the consolidated balance sheets. Travel Services Reynolds Jet Management The Company incurs expenses for travel services for company executives provided by a private aviation charter company that is owned by the chief executive officer and the senior vice president of operations of the Company (“private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $1.1 million, $1.0 million and $0.9 million during the years ended December 31, 2017, 2016 and 2015, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. Common Stock Purchases During 2015, an employee of the Company entered into a stock purchase agreement (“SPA”) with the Company that permitted the purchase of 37,037 shares of the Company’s common stock at the then-current value for those shares. There was no stock-based compensation expense recognized in relation to the SPA due to no required services to be rendered in exchange for shares. The proceeds from this SPA are reflected as Proceeds from sale of common stock in the consolidated statement of cash flows for the year ended December 31, 2015. Assets and Obligations Related to Former Owners Pursuant to the Medpace, Inc. Stock Purchase Agreement dated June 17, 2011 (the “Predecessor Purchase Agreement”), certain tax indemnifications between the sellers (a group led by the former majority shareholder who is the current chief executive officer, the “Former Owners”) and the buyers (led by CCMP) were entered into regarding contingencies that could arise after the June 17, 2011 transaction, as well as tax payments or refunds that were finalized after June 17, 2011 but which relate to periods prior to the Predecessor Purchase Agreement date. In February 2015, a settlement was reached with a local taxing authority regarding the refund of income tax payments made by the Company prior to June 17, 2011. The transactions were all fully settled in 2017. On the consolidated balance sheets at December 31, 2016, the Company had $0.1 million in Prepaid expenses and other current assets and Other assets related to the tax refund due from the local taxing authority and $0.1 million in Other current liabilities and Other long-term liabilities representing the obligation to the Former Owners. The Company had less than $0.1 million in Prepaid expenses and other current assets and $0.0 million in Other current liabilities on the consolidated balance sheets at December 31, 2016, associated with refunds from various other taxing authorities that were generated prior to June 17, 2011.

Cash Flow Statement- Supplemental Information

12 Months Ended

Dec. 31, 2017

Supplemental Cash Flow Information [Abstract]

Cash Flow Statement- Supplemental Information

15. CASH FLOW STATEMENT – SUPPLEMENTAL INFORMATION

During the year ended December 31, 2017, the Company engaged in the following significant non-cash investing and financing activities:

•

Acquired net assets totaling $0.7 million consisting of net Deferred tax assets of $21.1 million, offset by net Deferred tax liabilities of $0.1 million and Deferred credits of $20.3 million in exchange for Accounts receivable and unbilled, net of $0.6 million and Other assets of $0.1 million.

Entity Wide Disclosures

12 Months Ended

Dec. 31, 2017

Segment Reporting Entity Wide Disclosures [Abstract]

Entity Wide Disclosure

16. ENTITY WIDE DISCLOSURES

Operations By Geographic Location

The Company conducts operations in North America, Europe, Africa, Asia-Pacific and Latin America through wholly-owned subsidiaries and representative sales offices. The Company attributes service revenue to geographical locations based upon the location of the contracting entity. For the years ended December 31, 2017 and 2016, service revenue attributable to the U.S. represented approximately 98%, respectively, of total consolidated service revenue, net.

The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, if any (in thousands):


	2017		2016
Property and equipment, net:
United States	$	37,535	$	34,817
Europe		9,266		7,436
Other		1,938		1,552
Total property and equipment, net	$	48,739	$	43,805

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

17. QUARTERLY FINANCIAL DATA (unaudited)

The following table summarizes the Company's unaudited quarterly results of operations (in thousands, except per share data):

	2017
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter

Service revenue, net	$	93,781	$	94,552	$	98,681	$	99,448
Direct costs, excluding depreciation and amortization		51,105		51,955		53,144		55,569
Income from operations		15,944		16,279		17,198		15,437
Net income		8,447		9,553		9,831		11,291
Net income per share attributable to common shareholders - Basic	$	0.21	$	0.24	$	0.25	$	0.30
Net income per share attributable to common shareholders - Diluted	$	0.20	$	0.23	$	0.25	$	0.30

	2016
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter

Service revenue, net	$	87,800	$	92,633	$	94,812	$	95,376
Direct costs, excluding depreciation and amortization		46,981		49,234		51,221		51,074
Income (loss) from operations		12,869		14,114		12,617		12,890
Net income (loss)		3,448		4,962		5,036		(21	)
Net income (loss) per share attributable to common shareholders - Basic	$	0.11	$	0.15	$	0.14	$	(0.00	)
Net income (loss) per share attributable to common shareholders - Diluted	$	0.11	$	0.15	$	0.13	$	(0.00	)

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Share Repurchases

In November 2017, the Board members who are not affiliated with Cinven (the “Disinterested Directors”) approved an agreement to repurchase 2,000,000 shares of the Company’s common stock from Cinven in connection with the Secondary Offering (as described below) for aggregate consideration of approximately $60.3 million, representing a purchase price of $30.16 per share. The Company funded the repurchase with approximately $60.0 million in borrowings under the Senior Secured Revolving Credit Facility and cash on hand.

In August 2017, the Disinterested Directors of the Company approved a stock repurchase agreement with Medpace Limited Partnership, a Guernsey limited partnership (the “Limited Partnership” acting through its general partner, Medpace GP Limited, a Guernsey company, the “General Partner” and, the Limited Partnership acting through the General Partner, “Cinven”), pursuant to which the Company repurchased 2,000,000 shares of the Company’s common stock from Cinven for aggregate consideration of approximately $60.5 million, representing a purchase price of $30.27 per share. The Company funded the repurchase with cash on hand and $40.0 million in borrowings under our Senior Secured Revolving Credit Facility.

In April 2017, the Board of the Company authorized a share repurchase program with an authorized repurchase level of $50.0 million. The share repurchase program was cancelled in the fourth quarter of 2017. Repurchases under the repurchase program took place in the open market or negotiated transactions, at the discretion of the Company’s management. During the year ended December 31, 2017, the Company repurchased 1,342,786 shares of its outstanding common stock for $34.7 million under this share repurchase program.

The Company has elected to constructively retire all repurchased shares with all amounts paid in excess of Common stock par value reflected within Accumulated deficit in the Company’s consolidated balance sheets, except for 200,000 shares, which are reflected within treasury stock in the Company’s consolidated balance sheets.

Principles of Consolidation and Presentation

The Company records revenue net of any tax assessments by governmental authorities that are imposed and concurrent with specific revenue generating transactions.

Concentration of Credit Risk

Costs and Expenses

Reimbursed Out-of-Pocket Expenses

Income Taxes

Research and Development Credits

Stock-Based Compensation

The Company has stock-based employee compensation plans for which it incurs compensation expense.

Equity Awards

Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 (in thousands, except for earnings per share):



	Year Ended December 31,
	2017		2016		2015
Weighted-average shares:
Common shares outstanding		39,056		35,690		31,346
RSAs		90		88		-
Total weighted-average shares		39,146		35,778		31,346
Earnings per common share—Basic
Net income (loss)	$	39,122	$	13,425	$	(8,673	)
Less: Undistributed earnings allocated to RSAs		90		33		-
Net income (loss) available to common shareholders—Basic	$	39,032	$	13,392	$	(8,673	)

Net income (loss) per common share—Basic	$	1.00	$	0.38	$	(0.28	)

Basic weighted-average common shares outstanding		39,056		35,690		31,346
Effect of diluted shares		783		639		-
Diluted weighted-average shares outstanding		39,839		36,329		31,346

Net income (loss) per common share—Diluted	$	0.98	$	0.37	$	(0.28	)

Fair Value Measurements

Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities.

Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data.

Cash and Cash Equivalents, including Restricted Cash

Accounts Receivable and Unbilled, Net

Inventory

Property and Equipment

Leases

Goodwill and Intangible Assets

Goodwill

Intangible Assets

Impairment of Long-Lived Assets

Advanced Billings

Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized.

Deemed Landlord Liabilities

Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties.

Deferred Credit

Other Current Liabilities and Other Long-Term Liabilities

Recently Adopted and Issued Accounting Standards

Recently Adopted Accounting Standards

•

Upon adoption, no other aspects of ASU 2016-09 had an effect on the Company's consolidated financial statements or related footnote disclosures.

Recently Issued Accounting Standards

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS

The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2017, 2016 and 2015 (in thousands, except for earnings per share):



	Year Ended December 31,
	2017		2016		2015
Weighted-average shares:
Common shares outstanding		39,056		35,690		31,346
RSAs		90		88		-
Total weighted-average shares		39,146		35,778		31,346
Earnings per common share—Basic
Net income (loss)	$	39,122	$	13,425	$	(8,673	)
Less: Undistributed earnings allocated to RSAs		90		33		-
Net income (loss) available to common shareholders—Basic	$	39,032	$	13,392	$	(8,673	)

Net income (loss) per common share—Basic	$	1.00	$	0.38	$	(0.28	)

Basic weighted-average common shares outstanding		39,056		35,690		31,346
Effect of diluted shares		783		639		-
Diluted weighted-average shares outstanding		39,839		36,329		31,346

Net income (loss) per common share—Diluted	$	0.98	$	0.37	$	(0.28	)

Accounts Receivable And Unbilled, Net (Tables)

12 Months Ended

Dec. 31, 2017

Receivables [Abstract]

Schedule of Accounts Receivable and Unbilled, Net

Accounts receivable and unbilled, net consisted of the following at December 31 (in thousands):


	2017		2016
Accounts receivable	$	55,599	$	48,270
Unbilled	28,153			34,719
Less allowance for doubtful accounts	(673)		(3,222)
Total accounts receivable and unbilled, net	$	83,079	$	79,767

Schedule of Allowance for Doubtful Account Activity

A rollforward of allowance for doubtful account activity is as follows:


	Year Ended December 31,
	2017			2016			2015
Allowance for doubtful accounts - beginning balance	$	(3,222	)	$	(1,724	)	$	(5,855	)
Current year provision		(250	)		(2,166	)		(642	)
Write-offs, recoveries and the effects of foreign currency exchange		2,799			668			4,773
Allowance for doubtful accounts - ending balance	$	(673	)	$	(3,222	)	$	(1,724	)

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following at December 31 (in thousands):


	2017			2016
Land	$	972		$	543
Equipment		12,171			10,094
Furniture, fixtures, and leasehold improvements		21,280			15,415
Computer hardware, software, and phone equipment		9,571			7,535
Buildings		2,559			2,253
Deemed assets from landlord building construction		22,752			22,752
Construction-in-progress		5,554			2,840
Property and equipment at cost		74,859			61,432
Less: Accumulated depreciation		(26,120	)		(17,627	)
Property and equipment, net	$	48,739		$	43,805

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill are as follows (in thousands):

Balance as of December 31, 2015	$	660,981
Impairment of Goodwill	-
Balance as of December 31, 2017 and 2016	$	660,981

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following at December 31 (in thousands):



	2017			2016
Intangible assets:
Finite-lived intangible assets:
Carrying amount:
Backlog	$	72,630		$	72,630
Customer relationships		145,051			145,051
Developed technologies		54,475			54,475
Other		3,074			2,505
Total finite-lived intangible assets		275,230			274,661
Accumulated amortization:
Backlog		(72,630	)		(72,630	)
Customer relationships		(92,661	)		(66,267	)
Developed technologies		(40,856	)		(29,961	)
Other		(1,989	)		(1,378	)
Total accumulated amortization		(208,136	)		(170,236	)
Total finite-lived intangible assets, net		67,094			104,425
Trade name (indefinite-lived)		31,646			31,646
Total intangible assets, net	$	98,740		$	136,071

Schedule of Estimated Amortization Expense of Intangible Assets

As of December 31, 2017, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands):


2018	$	29,561
2019		14,829
2020		7,876
2021		5,114
2022		3,353
Later years		6,361
	$	67,094

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following at December 31 (in thousands):


	2017		2016
Employee compensation and benefits	$	19,707	$	21,453
Other		3,966		2,964
Total accrued expenses	$	23,673	$	24,417

Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following at December 31 (in thousands):



	2017			2016

Revolving credit facility	$	70,000		$	-
Term loan		152,625			165,000
Less unamortized discount		(399	)		(534	)
Less unamortized term loan debt issuance costs		(615	)		(824	)
Less current portion of long-term debt		(16,500	)		(12,375	)
Long-term debt, net, less current portion	$	205,111		$	151,267

Schedule of Principal Payments on Debt Due

Principal payments on debt are due as follows (in thousands):


2018		16,500
2019		16,500
2020		20,625
2021		169,000
Total	$	222,625

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Commitments, Contingencies, and Guarantees (Tables)

12 Months Ended

Dec. 31, 2017

Commitments And Contingencies Disclosure [Abstract]

Schedule of Minimum Future Lease Payments

As of December 31, 2017, minimum future lease payments required under these leases are as follows (in thousands):

			Non-Related		Total
	Related Party		Parties Operating		Operating
	Operating Lease		Leases		Leases
2018	$	2,164	$	4,841	$	7,005
2019		2,164		3,052		5,216
2020		2,164		2,459		4,623
2021		2,164		1,979		4,143
2022		1,803		1,709		3,512
Thereafter		-		3,264		3,264
Total minimum lease payments	$	10,459	$	17,304	$	27,763

Schedule of Minimum Annual Payments Required in Conjunction with Landlord Liability

As of December 31, 2017, minimum annual payments required in conjunction with the Deemed landlord liabilities are as follows (in thousands):

	Related Party				Total
	Minimum Lease		Less:		Principal
	Payments		Interest		Amounts Due
2018	$	3,852	$	1,960	$	1,892
2019		3,937		1,819		2,118
2020		3,988		1,662		2,326
2021		4,039		1,490		2,549
2022		4,092		1,301		2,791
Thereafter		19,842		3,024		16,818
Total	$	39,750	$	11,256	$	28,494

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of Weighted-Average Assumptions Used in BSM Model to Calculate Fair Value of Options

The following table sets forth the key weighted-average assumptions used in the BSM Model to calculate the fair value of options:



	Year Ended December 31,
	2017		2016		2015
Expected holding period - years	5.4		3.6		4.2
Expected volatility	28.0%			30.2%		36.4%
Risk-free interest rate	2.0%			1.0%		1.2%
Expected dividend yield		0.0%		0.0%		0.0%

Schedule of Grant Date Fair Value and Stock-based Compensation Expense Allocated



	Year Ended December 31,
	2017		2016		2015
Weighted average, grant date fair value
Stock Options	$	8.54	$	6.91	$	3.81
Restricted shares (RSAs and RSUs)	$	31.90	$	15.08	$	12.53

Stock-based compensation expense allocated to:
Direct costs, excluding depreciation and amortization	$	2,128	$	5,555	$	9,243
Selling, general, and administrative		2,335		4,260		13,081
Total stock-based compensation expense	$	4,463	$	9,815	$	22,324

Schedule of Stock Option Activity

The following table sets forth the Company’s stock option activity:


	Year Ended December 31,
	2017					2016					2015
				Weighted Average					Weighted Average					Weighted Average
	Options			Exercise Price		Options			Exercise Price		Shares			Exercise Price
Outstanding - beginning of Period		2,350,166		$	17.57		1,794,709		$	15.42		1,091,048		$	14.40
Granted		853,896		$	28.67		683,001		$	22.80		889,849		$	16.67
Exercised		(116,787	)	$	15.52		(36,980	)	$	14.50		(17,404	)	$	14.41
Forfeited/Expired		(304,407	)	$	20.55		(90,564	)	$	15.85		(168,784	)	$	15.53
Outstanding - end of period		2,782,868		$	20.73		2,350,166		$	17.57		1,794,709		$	15.42

Exercisable - end of period		917,592		$	15.40		647,343		$	15.22		242,777		$	14.40

Schedule of Restricted Share Activity

The following table sets forth the Company’s Restricted Share activity:



	Year Ended December 31,
	2017			2016			2015
	Shares			Shares			Shares
Outstanding and unvested - beginning of period		59,258			90,697			407,171
Granted		156,000			11,111			1,253,924
Vested		(29,629	)		(41,069	)		(1,530,547	)
Forfeited		(2,000	)		(1,481	)		(39,851	)
Outstanding and unvested - end of period		183,629			59,258			90,697

Cumulative vested shares - end of period		1,884,287			1,854,658			1,813,589

Schedule of Stock Options Expected To Vest, Stock Options Exercisable, and Unvested Restricted Share Awards Expected To Vest

The following table summarizes information about stock options expected to vest, stock options exercisable, and unvested restricted share awards expected to vest at December 31, 2017:

	Weighted Average						Weighted Average
	Exercise		Stock		Restricted		Remaining
	Price		Options		Shares		Life (Years)
December 31, 2017
Number of stock options expected to vest	$	20.73		2,782,868		-		4.9
Number of Restricted Shares expected to vest				-		183,629
Total expected to vest - December 31, 2017				2,782,868		183,629
Total stock options exercisable - December 31, 2017	$	15.40		917,592				3.8
Unrecognized compensation cost - December 31, 2017 (in thousands)			$	8,833	$	4,745
Weighted average years over which unrecognized compensation cost will be recognized				1.9		3.3

Schedule of Aggregate Intrinsic Value of Stock Options Exercised, Fair Values of Awards Vested, and Share Based Liabilities Settled



	Year Ended December 31,
	2017		2016		2015
Total intrinsic value of stock options exercised	$	1,619	$	403	$	(36	)
Total grant-date fair value of stock options vested	$	1,317	$	1,384	$	1,168
Total grant-date fair value of restricted shares vested	$	447	$	614	$	18,284
Total settlement date fair value of restricted shares vested	$	1,074	$	1,236	$	21,134
Total share-based liabilities settled	$	-	$	76	$	16,858

Income Taxes - (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Components of (Loss) Income Before Income Taxes

The components of income (loss) before income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017		2016		2015
Domestic	$	52,986	$	18,016	$	(12,294	)
Foreign jurisdictions	$	3,959	$	3,941	$	4,464
Income (loss) before income taxes	$	56,945	$	21,957	$	(7,830	)

Schedule of Income Tax Provision (Benefit)

Income tax provision (benefit) consisted of the following (in thousands):

	Current		Deferred			Total
Year ended December 31, 2017
U.S. Federal	$	10,953	$	3,466		$	14,419
U.S. state and local		2,032		51			2,083
Foreign jurisdictions		1,576		(255	)		1,321
	$	14,561	$	3,262		$	17,823

Year ended December 31, 2016
U.S. Federal	$	15,105	$	(8,784	)	$	6,321
U.S. state and local		1,636		(524	)		1,112
Foreign jurisdictions		710		389			1,099
	$	17,451	$	(8,919	)	$	8,532

Year ended December 31, 2015
U.S. Federal	$	11,067	$	(11,995	)	$	(928	)
U.S. state and local		1,119		(761	)		358
Foreign jurisdictions		1,372		41			1,413
	$	13,558	$	(12,715	)	$	843

Summary Of Difference Between Statutory Rate for Federal Income Tax and Effective Income Tax Rate

The difference between the statutory rate for federal income tax and the effective income tax rate was as follows (in thousands):



	Year Ended December 31,
	2017					2016					2015
Income tax expense calculated at the federal statutory rate	$	19,931		35.0	%	$	7,685		35.0	%	$	(2,740	)		35.0	%
Effect of:
State and local taxes, net of federal benefit		1,606		2.8			912		4.2			487			(6.2	)
Tax on foreign earnings, net of tax credits and deductions		(69	)	(0.1	)		(26	)	(0.1	)		(330	)		4.2
Tax reform adjustment		(3,418	)	(6.0	)
Deferred credit		(1,053	)	(1.9	)
Change in valuation allowance		-		-			-		-			-			-
Permanent items:
Goodwill impairment		-		-			-		-			2,106			(26.9	)
Stock-based awards		(179	)	(0.3	)		(534	)	(2.4	)		778			(9.9	)
Tax reform adjustment		574		1.0			-		-			-			-
Other		483		0.9			174		0.8			185			(2.4	)
State/Local tax credits		(1,187	)	(2.1	)		(1,049	)	(4.8	)		(931	)		11.9
Change in liability for uncertain tax positions		1,141		2.0			1,212		5.5			1,250			(16.0	)
Other		(6	)	(0.0	)		158		0.7			38			(0.5	)
	$	17,823		31.3	%	$	8,532		38.9	%	$	843		(10.8)%

Schedule of Components of Company's Net Deferred Tax Asset (Liability)

Components of the Company’s net deferred tax asset (liability) included in the consolidated balance sheets consisted of the following at December 31 (in thousands):


	2017			2016
Deferred tax assets:
Accrued liabilities	$	17,563		$	19,393
Depreciation and amortization		980			1,787
Foreign operating loss carryforward		246			246
U.S. federal tax credits and carryforward		8,152			-
U.S. state and local tax credits and carryforward		1,799			385
Other		667			1,209
Valuation allowance		(2,394	)		(987	)
Total deferred tax assets		27,013			22,033

Deferred tax liabilities:
Depreciation and amortization		(20,117	)		(33,436	)
Prepaid expenses		(572	)		(310	)
Other		(541	)		(220	)
Total deferred tax liabilities		(21,230	)		(33,966	)
Net deferred tax asset (liability)	$	5,783		$	(11,933	)

Schedule of Annual Activity Related to Valuation Allowance

Annual activity related to the Company’s valuation allowance is as follows (in thousands):



	Year Ended December 31,
	2017			2016			2015
Beginning Balance	$	987		$	1,021		$	1,086
Additions charged to expense		-			-			-
Additions due to asset acquisition		2,033			-			-
Reductions from utilization, reassessments and expirations		3			(34	)		(65	)
Remeasurement due to effect of tax reform		(629	)		-			-
Ending Balance	$	2,394		$	987		$	1,021

Schedule of Gross Unrecognized Tax Benefits

A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2017		2016			2015
Beginning Balance	$	5,698	$	2,604		$	1,353
Increases in tax positions for prior years		5		-			-
Decreases in tax positions for prior years		-		(196	)		(14	)
Increases in tax positions for current year		1,187		3,365			1,265
Lapse in statute of limitations		-		(75	)		-
Ending Balance	$	6,890	$	5,698		$	2,604

Miscellaneous Expense, Net (Tables)

12 Months Ended

Dec. 31, 2017

Other Income And Expenses [Abstract]

Components of Miscellaneous Expense, Net

Miscellaneous expense, net consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016			2015
Net loss on foreign-currency transactions	$	(1,004	)	$	(660	)	$	(1,307	)
Other income		650			237			174
Miscellaneous expense, net	$	(354	)	$	(423	)	$	(1,133	)

Entity Wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting Entity Wide Disclosures [Abstract]

Summary of Property and Equipment, Net by Geographic Region


	2017		2016
Property and equipment, net:
United States	$	37,535	$	34,817
Europe		9,266		7,436
Other		1,938		1,552
Total property and equipment, net	$	48,739	$	43,805

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Unaudited Quarterly Results of Operations

The following table summarizes the Company's unaudited quarterly results of operations (in thousands, except per share data):

	2017
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter

Service revenue, net	$	93,781	$	94,552	$	98,681	$	99,448
Direct costs, excluding depreciation and amortization		51,105		51,955		53,144		55,569
Income from operations		15,944		16,279		17,198		15,437
Net income		8,447		9,553		9,831		11,291
Net income per share attributable to common shareholders - Basic	$	0.21	$	0.24	$	0.25	$	0.30
Net income per share attributable to common shareholders - Diluted	$	0.20	$	0.23	$	0.25	$	0.30

	2016
	First Quarter		Second Quarter		Third Quarter		Fourth Quarter

Service revenue, net	$	87,800	$	92,633	$	94,812	$	95,376
Direct costs, excluding depreciation and amortization		46,981		49,234		51,221		51,074
Income (loss) from operations		12,869		14,114		12,617		12,890
Net income (loss)		3,448		4,962		5,036		(21	)
Net income (loss) per share attributable to common shareholders - Basic	$	0.11	$	0.15	$	0.14	$	(0.00	)
Net income (loss) per share attributable to common shareholders - Diluted	$	0.11	$	0.15	$	0.13	$	(0.00	)

Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Aug. 16, 2016	Nov. 30, 2017	Aug. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 30, 2017
Basis Of Presentation [Line Items]
Repurchases of common stock, value				$ 155,583	$ 0	$ 0
Treasury stock shares				200,000
Repayments of outstanding borrowings				$ 30,000	0	0
Offering expenses				0	$ 2,719	$ 0
2014 Senior Secured Term Loan Facility
Basis Of Presentation [Line Items]
Repayments of outstanding borrowings	$ 175,000
Share Repurchase Program
Basis Of Presentation [Line Items]
Repurchases of common stock, value				$ 34,700
Repurchases of outstanding common stock, shares				1,342,786
Maximum
Basis Of Presentation [Line Items]
Stock repurchase program, authorized amount							$ 50,000
Senior Secured Revolving Credit Facility
Basis Of Presentation [Line Items]
Share repurchases funding through borrowings			$ 40,000
Cinven
Basis Of Presentation [Line Items]
Repurchases of common stock, value			$ 60,500
Purchase price of repurchased shares			$ 30.27
Repurchases of outstanding common stock, shares			2,000,000
Secondary Offering
Basis Of Presentation [Line Items]
Percentage of outstanding common stock owned				46.20%
Secondary Offering \| Operating Expenses
Basis Of Presentation [Line Items]
Professional fees				$ 400
Secondary Offering \| Senior Secured Revolving Credit Facility
Basis Of Presentation [Line Items]
Share repurchases funding through borrowings		$ 60,000
Secondary Offering \| Cinven
Basis Of Presentation [Line Items]
Repurchases of outstanding common stock, shares		2,000,000
Repurchases of common stock, value		$ 60,300
Purchase price of repurchased shares		$ 30.16
Shares issued and sold				4,600,000
Initial Public Offering
Basis Of Presentation [Line Items]
Shares issued and sold, price per share	$ 23.00
Shares issued and sold	8,050,000
Net proceeds from issuance IPO	$ 173,600
Offering expenses	$ 2,700
Exercise of Underwriters' Option
Basis Of Presentation [Line Items]
Shares issued and sold	1,050,000

Acquisition - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Noncash Or Part Noncash Acquisitions [Line Items]
Deferred tax assets		$ 21,100
Deferred tax liabilities		100
Deferred credit		$ 11,468	$ 0
NephroGenex, Inc.
Noncash Or Part Noncash Acquisitions [Line Items]
Bankruptcy proceedings unsecured claim in exchange of common stock percentage	100.00%
Consideration paid	$ 1,200
Intangible assets	500
Deferred tax assets	22,200
Tax effected net operating losses	13,500
Tax effected capitalized research and development expenses	8,500
Tax effected federal tax credits	200
Deferred tax liabilities	100
Deferred credit	$ 21,400

Summary of Significant Accounting Policies - Additional Information (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) Customer shares	Dec. 31, 2016 USD ($) Customer shares	Dec. 31, 2015 USD ($) shares
Summary Of Significant Accounting Policies [Line Items]
Sales rebates	$ 200,000		$ 100,000
Number of customers accounted for more than 10% of accounts receivable \| Customer	0	0
Disbursement of pre-funded study costs	$ 138,700,000	$ 150,300,000	114,400,000
Fair value measurements transfers between level 1, level 2, or level 3	$ 0	$ 0	$ 0
Stock Options
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS \| shares	63	0	1,794
RSAs and RSUs
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS \| shares	0	0	660
Maximum
Summary Of Significant Accounting Policies [Line Items]
Sales rebates		$ 100,000
Estimated useful life of intangible assets	15 years
Maximum \| Accounting Standard Update (“ASU”) No. 2016-09
Summary Of Significant Accounting Policies [Line Items]
Discrete Adjustments to Income Tax Expense Benefit	$ 100,000
Maximum \| Computer Hardware Software Phone and Medical Imaging Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	5 years
Maximum \| Furniture and Fixtures and Other Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	7 years
Maximum \| Buildings
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	40 years
Maximum \| Computer Software Developed Costs
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	3 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	17 months
Minimum \| Computer Hardware Software Phone and Medical Imaging Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	3 years
Minimum \| Furniture and Fixtures and Other Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	5 years
Minimum \| Buildings
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets	30 years
Miscellaneous Expense, Net
Summary Of Significant Accounting Policies [Line Items]
Net loss on foreign currency transactions	$ (1,000,000)	(700,000)	$ (1,300,000)
Selling, General and Administrative
Summary Of Significant Accounting Policies [Line Items]
Advertisement expenses	$ 600,000	$ 600,000	$ 400,000

Summary of Significant Accounting Policies - Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted-average shares:
Basic weighted-average common shares outstanding									39,056	35,690	31,346
Total weighted-average shares									39,146	35,778	31,346
Earnings per common share—Basic
Net income (loss)	$ 11,291	$ 9,831	$ 9,553	$ 8,447	$ (21)	$ 5,036	$ 4,962	$ 3,448	$ 39,122	$ 13,425	$ (8,673)
Net income (loss) available to common shareholders—Basic									$ 39,032	$ 13,392	$ (8,673)
Net income (loss) per common share—Basic	$ 0.30	$ 0.25	$ 0.24	$ 0.21	$ 0.00	$ 0.14	$ 0.15	$ 0.11	$ 1.00	$ 0.38	$ (0.28)
Basic weighted-average common shares outstanding									39,056	35,690	31,346
Effect of diluted shares									783	639	0
Diluted weighted-average shares outstanding									39,839	36,329	31,346
Net income (loss) per common share—Diluted	$ 0.30	$ 0.25	$ 0.23	$ 0.20	$ 0.00	$ 0.13	$ 0.15	$ 0.11	$ 0.98	$ 0.37	$ (0.28)
RSAs
Weighted-average shares:
Basic weighted-average common shares outstanding									90	88	0
Earnings per common share—Basic
Less: Undistributed earnings allocated to RSAs									$ 90	$ 33	$ 0
Basic weighted-average common shares outstanding									90	88	0
Common Stock
Weighted-average shares:
Basic weighted-average common shares outstanding									39,056	35,690	31,346
Earnings per common share—Basic
Basic weighted-average common shares outstanding									39,056	35,690	31,346

Accounts Receivable And Unbilled, Net - Schedule of Accounts Receivable and Unbilled, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 13, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounts Notes And Loans Receivable Net Current [Abstract]
Accounts receivable	$ 55,599	$ 48,270
Unbilled	28,153	34,719
Less allowance for doubtful accounts	(673)	(3,222)	$ (3,222)	$ (1,724)	$ (5,855)
Total accounts receivable and unbilled, net	$ 83,079	$ 79,767

Accounts Receivable And Unbilled, Net - Schedule of Allowance for Doubtful Account Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounts Notes And Loans Receivable Net Current [Abstract]
Allowance for doubtful accounts - beginning balance	$ (3,222)	$ (1,724)	$ (5,855)
Current year provision	(250)	(2,166)	(642)
Write-offs, recoveries and the effects of foreign currency exchange	2,799	668	4,773
Allowance for doubtful accounts - ending balance	$ (673)	$ (3,222)	$ (1,724)

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property Plant and Equipment [Line Items]
Property and equipment at cost	$ 74,859	$ 61,432
Less: Accumulated depreciation	(26,120)	(17,627)
Property and equipment, net	48,739	43,805
Land
Property Plant and Equipment [Line Items]
Property and equipment at cost	972	543
Equipment
Property Plant and Equipment [Line Items]
Property and equipment at cost	12,171	10,094
Furniture, fixtures, and leasehold improvements
Property Plant and Equipment [Line Items]
Property and equipment at cost	21,280	15,415
Computer hardware, software, and phone equipment
Property Plant and Equipment [Line Items]
Property and equipment at cost	9,571	7,535
Buildings
Property Plant and Equipment [Line Items]
Property and equipment at cost	2,559	2,253
Deemed assets from landlord building construction
Property Plant and Equipment [Line Items]
Property and equipment at cost	22,752	22,752
Construction-in-Progress
Property Plant and Equipment [Line Items]
Property and equipment at cost	$ 5,554	$ 2,840

Property and Equipment, Net - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2011 Lease
Property Plant And Equipment [Abstract]
Depreciation \| $	$ 8,574	$ 7,442	$ 6,379
Description of capital leases	The leases expire in 2027 and the Company has one 10-year option to extend the term of the leases
Number of lease agreements \| Lease				2
Description of capital leases	The Deemed Assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease.

Goodwill and Intangible Assets - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended			24 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance		$ 660,981	$ 660,981		$ 660,981
Impairment of Goodwill	$ (9,300)	0	0	$ (9,313)	0
Goodwill, Ending Balance	$ 660,981	$ 660,981	$ 660,981	$ 660,981	$ 660,981

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended			24 Months Ended
	Dec. 31, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Goodwill and Intangible Assets [Line Items]
Goodwill, impairment charge	$ 9,300	$ 0	$ 0	$ 9,313	$ 0
Fair value assets measured on non-recurring basis		950,717	979,105		950,717
Goodwill	$ 660,981	660,981	$ 660,981	$ 660,981	660,981
Fair Value Measurement Non-Recurring \| Level 3
Goodwill and Intangible Assets [Line Items]
Fair value assets measured on non-recurring basis		692,600			692,600
Goodwill		661,000			661,000
Indefinite-lived intangible assets		$ 31,600			$ 31,600

Goodwill and Intangible Assets - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-lived intangible assets:
Total finite-lived intangible assets	$ 275,230	$ 274,661
Accumulated amortization:
Total accumulated amortization	(208,136)	(170,236)
Total finite-lived intangible assets, net	67,094	104,425
Trade name (indefinite-lived)	31,646	31,646
Total intangible assets, net	98,740	136,071
Backlog
Finite-lived intangible assets:
Total finite-lived intangible assets	72,630	72,630
Accumulated amortization:
Total accumulated amortization	(72,630)	(72,630)
Customer Relationships
Finite-lived intangible assets:
Total finite-lived intangible assets	145,051	145,051
Accumulated amortization:
Total accumulated amortization	(92,661)	(66,267)
Developed Technologies
Finite-lived intangible assets:
Total finite-lived intangible assets	54,475	54,475
Accumulated amortization:
Total accumulated amortization	(40,856)	(29,961)
Other
Finite-lived intangible assets:
Total finite-lived intangible assets	3,074	2,505
Accumulated amortization:
Total accumulated amortization	$ (1,989)	$ (1,378)

Goodwill and Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
2018	$ 29,561
2019	14,829
2020	7,876
2021	5,114
2022	3,353
Later years	6,361
Total finite-lived intangible assets, net	$ 67,094	$ 104,425

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued Liabilities And Other Liabilities [Abstract]
Employee compensation and benefits	$ 19,707	$ 21,453
Other	3,966	2,964
Total accrued expenses	$ 23,673	$ 24,417

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt	$ 222,625
Less unamortized discount	(399)	$ (534)
Less unamortized term loan debt issuance costs	(615)	(824)
Less current portion of long-term debt	(16,500)	(12,375)
Long-term debt, net, less current portion	205,111	151,267
Revolving credit facility
Debt Instrument [Line Items]
Debt	70,000
Term loan
Debt Instrument [Line Items]
Debt	$ 152,625	$ 165,000

Debt - Schedule of Principal Payments on Debt Due (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Debt Disclosure [Abstract]
2018	$ 16,500
2019	16,500
2020	20,625
2021	169,000
Total	$ 222,625

Debt - Additional Information (Details) - USD ($)		9 Months Ended	12 Months Ended
Debt - Additional Information (Details) - USD ($)	Dec. 08, 2016	Dec. 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 01, 2014
Debt Instrument [Line Items]
Description of variable interest rate basis			Borrowings under the 2014 Senior Secured Credit Facilities incurred interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 3.75% if our total net leverage ratio was less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate was deemed to be no less than 1.00% per annum; (b) a base rate, which was defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 2.75% if our total leverage ratio was less than or equal to 4.75:1.00; provided that the base rate was deemed to be no less than 2.00% per annum. In addition, the Company was required to pay to the lenders a commitment fee of 0.5% quarterly for unused commitments on the 2014 Senior Secured Revolving Credit Facility, subject to a step-down to 0.375% based upon achievement of a certain leverage ratio as defined within the 2014 Senior Secured Credit Facilities.
Outstanding borrowings			$ 222,625,000
Unamortized issue discount			399,000	$ 534,000
Origination fees			615,000	824,000
Cash and cash equivalents			26,485,000	37,099,000
Loss on extinguishment of debt			$ 0	10,726,000	$ 0
Eurocurrency Rate \| 2014 Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			4.00%
Federal Funds Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			0.50%
Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.00%
Base Rate \| 2014 Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.00%
Base Rate \| 2014 Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			3.00%
Minimum \| Eurocurrency Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio			475.00%
Minimum \| Base Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio			475.00%
Maximum \| Eurocurrency Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio			475.00%
Debt instrument, deemed interest rate			1.00%
Maximum \| Eurocurrency Rate \| 2014 Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			3.75%
Maximum \| Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.75%
Debt instrument, total net leverage ratio			475.00%
Debt instrument, deemed interest rate			2.00%
Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Unamortized issue discount	$ 500,000		$ 400,000	500,000
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Outstanding borrowings			$ 70,000,000
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Description of variable interest rate basis			Borrowings under the Senior Secured Credit Facilities bear interest at a rate equal to, at our option, either (i) the adjusted Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period plus an applicable margin from 1.25% to 2.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00, or (ii) an alternative base rate (determined by reference to the highest of (a) the prime commercial lending rate of the administrative agent, as established from time to time, (b) the Federal Funds Rate plus 0.50% and (c) the one-month adjusted Eurocurrency rate for loans in U.S. dollars plus 1.00%) plus an applicable margin from 0.25% to 1.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00. The applicable margin as of December 31, 2017 was 1.25% for eurocurrency loans and 0.25% for base rate loans.
Ratio of consolidated funded indebtedness to consolidated EBITDA			400.00%
Loss on extinguishment of debt				10,700,000
Debt instrument, third party fees				500,000
Debt instrument unamortized loan origination fee				10,200,000
Senior Secured Credit Facilities \| Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.25%
Senior Secured Credit Facilities \| Federal Funds Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			0.50%
Senior Secured Credit Facilities \| One-Month Adjusted Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.00%
Senior Secured Credit Facilities \| Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			0.25%
Senior Secured Credit Facilities \| Minimum \| Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.25%
Debt instrument, total net leverage ratio			3.75%
Senior Secured Credit Facilities \| Minimum \| Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			0.25%
Debt instrument, total net leverage ratio			1.50%
Senior Secured Credit Facilities \| Maximum
Debt Instrument [Line Items]
Ratio of consolidated funded indebtedness to consolidated EBITDA			450.00%
Cash consideration			$ 25,000,000
Ratio of consolidated EBITDA to consolidated interest expense			300.00%
Senior Secured Credit Facilities \| Maximum \| Unrestricted
Debt Instrument [Line Items]
Cash and cash equivalents				50,000,000
Senior Secured Credit Facilities \| Maximum \| Foreign \| Unrestricted
Debt Instrument [Line Items]
Cash and cash equivalents				25,000,000
Senior Secured Credit Facilities \| Maximum \| Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.25%
Debt instrument, total net leverage ratio			1.50%
Senior Secured Credit Facilities \| Maximum \| Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			1.25%
Debt instrument, total net leverage ratio			3.75%
Senior Secured Credit Facilities \| Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 165,000,000
Debt instrument percentage of face value issued	99.70%
Expiration date	2021-12
Origination fees	$ 800,000		$ 600,000	800,000
Senior Secured Credit Facilities \| Term Loan
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.82%
Senior Secured Credit Facilities \| Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 150,000,000
Expiration date	2021-12
Debt instrument, total net leverage ratio			300.00%
Commitment fee percentage		0.375%
Outstanding borrowings			$ 70,000,000	0
Undrawn capacity			80,000,000	150,000,000
Outstanding letters of credit			300,000	100,000
Origination fees	$ 1,600,000
Unamortized origination fees			$ 1,300,000	$ 1,600,000
Senior Secured Credit Facilities \| Senior Secured Revolving Credit Facility \| Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Commitment fee percentage			0.50%
Senior Secured Credit Facilities \| Senior Secured Revolving Credit Facility \| Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Commitment fee percentage			0.375%
Senior Secured Credit Facilities \| Senior Secured Revolving Credit Facility \| Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)			2.82%
2014 Senior Secured Credit Facilities \| 2014 Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 60,000,000
2014 Senior Secured Credit Facilities \| 2014 Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 530,000,000
Credit facility expiration year			2016

Commitments, Contingencies, and Guarantees - Schedule of Minimum Future Lease Payments (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Operating Leased Assets [Line Items]
Operating Lease, 2018	$ 7,005
Operating Lease, 2019	5,216
Operating Lease, 2020	4,623
Operating Lease, 2021	4,143
Operating Lease, 2022	3,512
Operating Lease, Thereafter	3,264
Operating Lease, Total minimum lease payments	27,763
Related Party
Operating Leased Assets [Line Items]
Operating Lease, 2018	2,164
Operating Lease, 2019	2,164
Operating Lease, 2020	2,164
Operating Lease, 2021	2,164
Operating Lease, 2022	1,803
Operating Lease, Thereafter	0
Operating Lease, Total minimum lease payments	10,459
Non-Related Party
Operating Leased Assets [Line Items]
Operating Lease, 2018	4,841
Operating Lease, 2019	3,052
Operating Lease, 2020	2,459
Operating Lease, 2021	1,979
Operating Lease, 2022	1,709
Operating Lease, Thereafter	3,264
Operating Lease, Total minimum lease payments	$ 17,304

Commitments, Contingencies, and Guarantees - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017 USD ($) Building	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2012 USD ($)
Commitments Contingencies And Guarantees [Line Items]
Number of buildings in corporate headquarters \| Building	3
Operating leases rental expense total	$ 7,900,000	$ 6,700,000	$ 5,800,000
Outstanding claims for payment			2,000,000
Proceeds from legal settlements			2,000,000
Minimum
Commitments Contingencies And Guarantees [Line Items]
Non-payment of outstanding invoices				$ 6,500,000
Selling, General and Administrative
Commitments Contingencies And Guarantees [Line Items]
Bad debt recovery			$ 2,000,000

Commitments, Contingencies, and Guarantees - Schedule of Minimum Annual Payments Required in Conjunction with Landlord Liability (Details) - Deemed Landlord Liabilities $ in Thousands	Dec. 31, 2017 USD ($)
Commitments Contingencies And Guarantees [Line Items]
Related Party Minimum Lease Payments, 2018	$ 3,852
Related Party Minimum Lease Payments, 2019	3,937
Related Party Minimum Lease Payments, 2020	3,988
Related Party Minimum Lease Payments, 2021	4,039
Related Party Minimum Lease Payments, 2022	4,092
Related Party Minimum Lease Payments, Thereafter	19,842
Related Party Minimum Lease Payments, Total	39,750
Related Part Minimum Lease Payments, Interest, 2018	1,960
Related Part Minimum Lease Payments, Interest, 2019	1,819
Related Part Minimum Lease Payments, Interest, 2020	1,662
Related Part Minimum Lease Payments, Interest, 2021	1,490
Related Part Minimum Lease Payments, Interest, 2022	1,301
Related Part Minimum Lease Payments, Interest, Thereafter	3,024
Related Part Minimum Lease Payments, Interest, Total	11,256
Total Principal Amounts Due, 2018	1,892
Total Principal Amounts Due, 2019	2,118
Total Principal Amounts Due, 2020	2,326
Total Principal Amounts Due, 2021	2,549
Total Principal Amounts Due, 2022	2,791
Total Principal Amounts Due, Thereafter	16,818
Total Principal Amounts Due, Total	$ 28,494

Shareholders' Equity - Additional Information (Details)	12 Months Ended
Shareholders' Equity - Additional Information (Details)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) employee shares	Aug. 16, 2016 shares	Aug. 11, 2016 shares	Dec. 31, 2014 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized	250,000,000	250,000,000		250,000,000
Preferred stock, shares authorized	5,000,000	5,000,000		5,000,000
Stock options granted	853,896	683,001	889,849
Share-based payment award description			If Medpace Investors exercised the call right, it could do so up to the later of twelve months following the employee’s departure date or six months following the determination that the former employee was directly or indirectly engaged in competitive business activities
Incremental stock based compensation expense \| $		$ 3,100,000
Stock-based compensation expense \| $	$ 4,463,000	9,815,000	$ 22,324,000
Stock-based compensation liability reclassified to additional paid in capital \| $		10,500,000
Stock-based compensation liability \| $	0	0
Actual tax benefits recognized related to stock-based compensation \| $	$ 500,000	$ 1,000,000	$ 4,600,000
Vesting Equally on Second, Third and Fourth Anniversary of Grant Date Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	15,000
Award vesting period	4 years
RSA Modification
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards held by employees			688,599
Number of current employees holding unvested restricted stock \| employee			158
Incremental stock based compensation expense \| $			$ 0
Stock-based compensation expense \| $			$ 5,700,000
Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted	156,000	11,111	1,253,924
Unvested restricted stock awards held by employees	183,629	59,258	90,697			407,171
Shares granted and immediately vested	0	11,111	583,021
Stock-based compensation liability	0	0	231,229
Residual vested shares granted			351,851
2016 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares registered and available for grant	6,000,000				6,000,000
Awards granted	1,009,896
Stock options granted		648,180
Shares available for future stock compensation grants	4,300,000	5,400,000
Plan expiration year	2026
2016 Incentive Award Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation option terms	10 years
2016 Incentive Award Plan \| Vesting on October 31, 2016 and Eight equal monthly Installments
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		21,530
Vesting percentage		33.00%
Award vesting description	stock options with various vesting schedules, but all of which vest within a calendar year of the respective grant date
2016 Incentive Award Plan \| Vesting After One Year \| Non-employee Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	41,346
Award vesting period	1 year
2016 Incentive Award Plan \| Stock Options \| Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	797,550	626,650
Award vesting period	4 years	4 years
2016 Incentive Award Plan \| Restricted Stock Awards (RSA) \| Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
Shares granted	118,000
2016 Incentive Award Plan \| Restricted Stock Units (RSU) \| Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
Shares granted	38,000
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation option terms	7 years
Stock options granted		45,932
2014 Equity Incentive Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	4 years
2014 Equity Incentive Plan \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period	3 years
2014 Equity Incentive Plan \| Vesting Equally Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		34,821
Award vesting period		4 years
2014 Equity Incentive Plan \| Fully Vested Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted		11,111

Shareholders' Equity -Schedule of Weighted-Average Assumptions Used in BSM Model to Calculate Fair Value of Options (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Expected holding period - years	5 years 4 months 24 days	3 years 7 months 6 days	4 years 2 months 12 days
Expected volatility	28.00%	30.20%	36.40%
Risk-free interest rate	2.00%	1.00%	1.20%
Expected dividend yield	0.00%	0.00%	0.00%

Shareholders' Equity - Schedule of Grant Date Fair Value and Stock-based Compensation Expense Allocated (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,463	$ 9,815	$ 22,324
Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted average, grant date fair value	$ 8.54	$ 6.91	$ 3.81
Restricted Shares (RSAs and RSUs)
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted average, grant date fair value	$ 31.90	$ 15.08	$ 12.53
Direct Costs, Excluding Depreciation and Amortization
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,128	$ 5,555	$ 9,243
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,335	$ 4,260	$ 13,081

Shareholders' Equity - Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Number of Options, Outstanding - beginning of Period	2,350,166	1,794,709	1,091,048
Number of Options, Granted	853,896	683,001	889,849
Number of Options, Exercised	(116,787)	(36,980)	(17,404)
Number of Options, Forfeited/Expired	(304,407)	(90,564)	(168,784)
Number of Options, Outstanding - end of period	2,782,868	2,350,166	1,794,709
Number of Options, Exercisable - end of period	917,592	647,343	242,777
Weighted Average Exercise Price, Outstanding - beginning of Period	$ 17.57	$ 15.42	$ 14.40
Weighted Average Exercise Price, Granted	28.67	22.80	16.67
Weighted Average Exercise Price, Exercised	15.52	14.50	14.41
Weighted Average Exercise Price, Forfeited/Expired	20.55	15.85	15.53
Weighted Average Exercise Price, Outstanding - end of period	20.73	17.57	15.42
Weighted Average Exercise Price, Exercisable - end of period	$ 15.40	$ 15.22	$ 14.40

Shareholders' Equity - Schedule of Restricted Share Activity (Details) - Restricted Shares (RSAs and RSUs) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding and unvested - beginning of period	59,258	90,697	407,171
Granted	156,000	11,111	1,253,924
Vested	(29,629)	(41,069)	(1,530,547)
Forfeited	(2,000)	(1,481)	(39,851)
Outstanding and unvested - end of period	183,629	59,258	90,697
Cumulative vested shares - end of period	1,884,287	1,854,658	1,813,589

Shareholders' Equity - Schedule of Stock Options Expected To Vest, Stock Options Exercisable, and Unvested Restricted Share Awards Expected To Vest (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price, Number of stock options expected to vest	$ 20.73
Weighted Average Exercise Price, Total stock options exercisable - December 31, 2017	$ 15.40	$ 15.22	$ 14.40
Number of stock options expected to vest	2,782,868
Number of Restricted Shares expected to vest	183,629
Weighted Average Remaining Life (Years), Number of stock options expected to vest	4 years 10 months 24 days
Weighted Average Remaining Life (Years), Total stock options exercisable - December 31, 2017	3 years 9 months 18 days
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options expected to vest	2,782,868
Total stock options exercisable - December 31, 2017	917,592
Unrecognized compensation cost - December 31, 2017	$ 8,833
Weighted average years over which unrecognized compensation cost will be recognized	1 year 10 months 24 days
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average years over which unrecognized compensation cost will be recognized	3 years 3 months 18 days
Number of Restricted Shares expected to vest	183,629
Unrecognized compensation cost - December 31, 2017	$ 4,745

Shareholder's Equity - Schedule of Aggregate Intrinsic Value of Stock Options Exercised, Fair Values of Awards Vested, and Share Based Liabilities Settled (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of stock options exercised	$ 1,619	$ 403	$ (36)
Total grant-date fair value of stock options vested	1,317	1,384	1,168
Total share-based liabilities settled	0	76	16,858
Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total grant-date fair value of restricted shares vested	447	614	18,284
Total settlement date fair value of restricted shares vested	$ 1,074	$ 1,236	$ 21,134

Employee Benefit Plans - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
401(k) Plan
Defined Contribution Plan Disclosure [Line Items]
Maximum annual contribution by employee, percentage of pre-tax earnings	50.00%
401(k) Plan \| U.S. Employees
Defined Contribution Plan Disclosure [Line Items]
Recognized cost of employee benefit plan	$ 2.3	$ 2.0	$ 1.7
Minimum period of service required for matching contribution eligibility	1 year
Minimum required period of service for employer contributions to fully vest	3 years
Defined Contribution Arrangements \| Non-U.S. Employees
Defined Contribution Plan Disclosure [Line Items]
Recognized cost of employee benefit plan	$ 0.9	$ 0.7	$ 0.7

Income Taxes - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
U.S. federal corporate tax rate			35.00%	35.00%	35.00%
Provisional tax benefit			$ 3,418,000	$ 0	$ 0
Provisional transition tax expense			$ 574,000	0	$ 0
Tax Cuts and Jobs Act of 2017, accounting complete true or false			false
Foreign operating loss carryforward			$ 246,000	246,000
Deferred tax assets, valuation allowance			$ 2,394,000	987,000
Percentage of foreign net operating loss carryforward			74.00%
Deferred tax assets			$ 21,100,000
Deferred tax liabilities			100,000
Liability for interest and penalties			1,400,000	1,000,000
Liability for uncertain tax position			$ 5,900,000	$ 4,300,000
Number of tax years			4 years
NephroGenex, Inc.
Income Tax Disclosure [Line Items]
Deferred tax assets	$ 22,200,000
Tax effected net operating losses	13,500,000
Tax effected capitalized research and development expenses	8,500,000
Tax effected federal tax credits	200,000
Deferred tax liabilities	$ 100,000
Minimum
Income Tax Disclosure [Line Items]
Foreign net operating loss carryforwards expiration year			2020
Minimum \| Tax Year 2014
Income Tax Disclosure [Line Items]
Open tax year			2014
Maximum
Income Tax Disclosure [Line Items]
Foreign net operating loss carryforwards expiration year			2025
Maximum \| Tax Year 2017
Income Tax Disclosure [Line Items]
Open tax year			2017
U.S. State and Local
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards			$ 1,300,000
U.S. State and Local \| Minimum
Income Tax Disclosure [Line Items]
Operating loss carryforwards expiration year			2026
U.S. State and Local \| Maximum
Income Tax Disclosure [Line Items]
Operating loss carryforwards expiration year			2032
Domestic Tax Authority
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards			$ 8,000,000
Domestic Tax Authority \| Minimum
Income Tax Disclosure [Line Items]
Operating loss carryforwards expiration year			2031
Domestic Tax Authority \| Maximum
Income Tax Disclosure [Line Items]
Operating loss carryforwards expiration year			2037
Foreign Tax Authority
Income Tax Disclosure [Line Items]
Deferred tax assets, valuation allowance			$ 200,000
Scenario, Forecast
Income Tax Disclosure [Line Items]
U.S. federal corporate tax rate		21.00%
Deduction for dividends received in tax reform act		100.00%
Dividends received from owned foreign corporations by us corporate shareholders		10.00%
Foreign corporations shareholders holding period		1 year

Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Domestic	$ 52,986	$ 18,016	$ (12,294)
Foreign jurisdictions	3,959	3,941	4,464
Income (loss) before income taxes	$ 56,945	$ 21,957	$ (7,830)

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]
U.S. Federal, Current	$ 10,953	$ 15,105	$ 11,067
U.S. Federal, Deferred	3,466	(8,784)	(11,995)
U.S. Federal, Total	14,419	6,321	(928)
U.S. state and local, Current	2,032	1,636	1,119
U.S. state and local, Deferred	51	(524)	(761)
U.S. state and local, Total	2,083	1,112	358
Foreign jurisdictions, Current	1,576	710	1,372
Foreign jurisdictions, Deferred	(255)	389	41
Foreign jurisdictions, Total	1,321	1,099	1,413
Income tax provision (benefit), Current	14,561	17,451	13,558
Income tax provision (benefit), Deferred	3,262	(8,919)	(12,715)
Income tax provision (benefit), Total	$ 17,823	$ 8,532	$ 843

Income Taxes - Summary Of Difference Between Statutory Rate for Federal Income Tax and Effective Income Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income tax expense calculated at the federal statutory rate	$ 19,931	$ 7,685	$ (2,740)
State and local taxes, net of federal benefit	1,606	912	487
Tax on foreign earnings, net of tax credits and deductions	(69)	(26)	(330)
Tax reform adjustment	(3,418)	0	0
Deferred credit	(1,053)	0	0
Change in valuation allowance	0	0	0
Goodwill impairment	0	0	2,106
Stock-based awards	(179)	(534)	778
Tax reform adjustment	574	0	0
Other	483	174	185
State/Local tax credits	(1,187)	(1,049)	(931)
Change in liability for uncertain tax positions	1,141	1,212	1,250
Other	(6)	158	38
Income Tax Expense (Benefit)	$ 17,823	$ 8,532	$ 843
Income tax expense calculated at the federal statutory rate	35.00%	35.00%	35.00%
State and local taxes, net of federal benefit	2.80%	4.20%	(6.20%)
Tax on foreign earnings, net of tax credits and deductions	(0.10%)	(0.10%)	4.20%
Tax reform adjustment	(6.00%)	0.00%	0.00%
Deferred credit	(1.90%)	(0.00%)	(0.00%)
Change in valuation allowance	0.00%	0.00%	0.00%
Goodwill impairment	0.00%	0.00%	(26.90%)
Stock-based awards	(0.30%)	(2.40%)	(9.90%)
Tax reform adjustment	1.00%	0.00%	0.00%
Other	0.90%	0.80%	(2.40%)
State/Local tax credits	(2.10%)	(4.80%)	11.90%
Change in liability for uncertain tax positions	2.00%	5.50%	(16.00%)
Other	0.00%	0.70%	(0.50%)
Effective Income Tax Rate Reconciliation, Percent	31.30%	38.90%	(10.80%)

Income Taxes - Schedule of Components of Company's Net Deferred Tax Asset (Liability) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Accrued liabilities	$ 17,563	$ 19,393
Depreciation and amortization	980	1,787
Foreign operating loss carryforward	246	246
U.S. federal tax credits and carryforward	8,152	0
U.S. state and local tax credits and carryforward	1,799	385
Other	667	1,209
Valuation allowance	(2,394)	(987)
Total deferred tax assets	27,013	22,033
Deferred tax liabilities:
Depreciation and amortization	(20,117)	(33,436)
Prepaid expenses	(572)	(310)
Other	(541)	(220)
Total deferred tax liabilities	(21,230)	(33,966)
Net deferred tax asset	$ 5,783
Net deferred tax (liability)		$ (11,933)

Income Taxes - Schedule of Annual Activity Related to Valuation Allowance(Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning Balance	$ 987	$ 1,021	$ 1,086
Additions charged to expense	0	0	0
Additions due to asset acquisition	2,033	0	0
Reductions from utilization, reassessments and expirations	3	(34)	(65)
Remeasurement due to effect of tax reform	(629)	0	0
Ending Balance	$ 2,394	$ 987	$ 1,021

Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance	$ 5,698	$ 2,604	$ 1,353
Increases in tax positions for prior years	5	0	0
Decreases in tax positions for prior years	0	(196)	(14)
Increases in tax positions for current year	1,187	3,365	1,265
Lapse in statute of limitations	0	(75)	0
Ending Balance	$ 6,890	$ 5,698	$ 2,604

Miscellaneous Expense, Net - Components of Miscellaneous Expense, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Income And Expenses [Abstract]
Net loss on foreign-currency transactions	$ (1,004)	$ (660)	$ (1,307)
Other income	650	237	174
Miscellaneous expense, net	$ (354)	$ (423)	$ (1,133)

Related Party Transactions - Additional Information (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($) Building RenewalOption Agreement	Dec. 31, 2016 USD ($) Parcel	Dec. 31, 2015 USD ($) shares	Dec. 31, 2012 USD ($)
Related Party Transaction [Line Items]
Service revenue with related parties		$ 11,100,000	$ 24,100,000	$ 24,000,000
Reimbursed out-of-pocket revenue with related parties		1,500,000	5,400,000	6,900,000
Reimbursed out-of-pocket expenses with related parties		1,500,000	5,400,000	6,900,000
Accounts receivable and unbilled, net		1,000,000	2,300,000
Advanced billings		1,700,000	7,600,000
Pre-funded study costs with related parties		1,000,000	3,900,000
Deemed landlord liability, long-term portions		26,602,000	28,527,000
Stock-based compensation expense		4,463,000	9,815,000	$ 22,324,000
Employee Stock Purchase Agreement
Related Party Transaction [Line Items]
Number of common stock purchase by employee \| shares				37,037
Stock-based compensation expense				$ 0
Cinven
Related Party Transaction [Line Items]
Management fees expense with related party			200,000	300,000
Travel expenses with related party		100,000	100,000	100,000
Accounts payable to related party			100,000
Director fees with related party		100,000	100,000
Cinven \| Maximum
Related Party Transaction [Line Items]
Accounts payable to related party		100,000
Medpace Investors
Related Party Transaction [Line Items]
Related party tax expense			800,000	900,000
Repayments of Related Party Debt			300,000
Proceeds from Related Party Debt			300,000
Prepaid Expenses and Other Current Assets \| U.S. State and Local
Related Party Transaction [Line Items]
Due from related party			100,000
Prepaid Expenses and Other Current Assets \| Maximum \| Other Taxing Authorities
Related Party Transaction [Line Items]
Due from related party			100,000
Other Assets \| U.S. State and Local
Related Party Transaction [Line Items]
Due from related party			100,000
Other Current Liabilities \| Maximum \| Other Taxing Authorities
Related Party Transaction [Line Items]
Due to related party			0
Other Current Liabilities \| Former Owner Member
Related Party Transaction [Line Items]
Due to related party			100,000
Other Long-term Liabilities \| Former Owner Member
Related Party Transaction [Line Items]
Due to related party			100,000
Employee Loans \| Prepaid Expenses and Other Current Assets and Other Assets
Related Party Transaction [Line Items]
Employee advances receivables		200,000
Employee Loans \| Other Assets
Related Party Transaction [Line Items]
Employee advances receivables			200,000
Service Agreements \| Symplmed
Related Party Transaction [Line Items]
Service revenue with related parties		0		1,200,000
Service Agreements \| Symplmed \| Maximum
Related Party Transaction [Line Items]
Service revenue with related parties		100,000	(100,000)
Service Agreements \| Coherus Bio Sciences Inc
Related Party Transaction [Line Items]
Service revenue with related parties		$ 8,000,000	22,300,000	22,100,000
Amount of investment					$ 2,500,000
Service agreement cancellation notice period		30 days
Reimbursed out-of-pocket revenue with related parties		$ 1,300,000	5,100,000	6,900,000
Reimbursed out-of-pocket expenses with related parties		1,300,000	5,100,000	$ 6,900,000
Accounts receivable and unbilled, net		300,000	2,000,000
Advanced billings		1,500,000	6,300,000
Pre-funded study costs with related parties		1,000,000	3,800,000
Service Agreements \| MX II Associates LLC
Related Party Transaction [Line Items]
Percentage of sales commission				10.00%
Commission paid				$ 1,100,000
Service Agreements \| Xenon
Related Party Transaction [Line Items]
Service revenue with related parties	$ 600,000		1,300,000
Reimbursed out-of-pocket revenue with related parties	100,000		200,000
Reimbursed out-of-pocket expenses with related parties	$ 100,000		200,000
Accounts receivable and unbilled, net			300,000
Advanced billings			1,300,000
Pre-funded study costs with related parties			100,000
Service Agreements \| Cymabay
Related Party Transaction [Line Items]
Service revenue with related parties		600,000	300,000	100,000
Accounts receivable and unbilled, net		100,000
Service Agreements \| Cymabay \| Maximum
Related Party Transaction [Line Items]
Accounts receivable and unbilled, net			100,000
Service Agreements \| LIB
Related Party Transaction [Line Items]
Service revenue with related parties		1,400,000	200,000
Accounts receivable and unbilled, net		500,000
Advanced billings		200,000
Service Agreements \| LIB \| Maximum
Related Party Transaction [Line Items]
Accounts receivable and unbilled, net			100,000
Advanced billings			$ 100,000
Service Agreements \| CinRx
Related Party Transaction [Line Items]
Service revenue with related parties		400,000
Purchase of Real Estate Properties \| Chief Executive Officer
Related Party Transaction [Line Items]
Number of parcel in real estate property \| Parcel			4
Purchase price of real estate property		$ 400,000
Transaction closed date		Jan. 11, 2017
Leased Real Estate \| Chief Executive Officer
Related Party Transaction [Line Items]
Term of lease		12 years
Lease expiration period		2022-11
Number of lease renewal, 10-year option \| RenewalOption		1
Lease term upon renewal		10 years
Annual base rent		$ 2,100,000
Lease expense recognized		$ 2,100,000	$ 2,100,000	2,100,000
Storage space lease basis		month to month basis
Leased Real Estate \| Chief Executive Officer And Immediate Family
Related Party Transaction [Line Items]
Number of lease renewal, 10-year option \| RenewalOption		1
Number of lease agreements \| Agreement		2
Number of buildings \| Building		2
Lease occupancy year		2012
Lease expiration year		2027
Lease term upon renewal		10 years
Term of lease		15 years
Related party capital lease payments		$ 3,800,000	3,700,000	3,400,000
Deemed landlord liability, current		1,900,000	1,700,000
Deemed landlord liability, long-term portions		26,600,000	28,500,000
Leased Real Estate \| Property and Equipment, Net \| Chief Executive Officer And Immediate Family \| Building
Related Party Transaction [Line Items]
Deemed assets, net		16,300,000	18,100,000
Travel Services \| Chief Executive Officer
Related Party Transaction [Line Items]
Travel expenses with related party		$ 1,100,000	$ 1,000,000	$ 900,000

Cash Flow Statement- Supplemental Information - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Supplemental Cash Flow Information [Abstract]
Acquisition of net assets	$ 0.7
Deferred tax assets, net	21.1
Deferred tax liabilities, net	0.1
Deferred credits	20.3
Accounts receivable and unbilled, net	0.6
Other assets	$ 0.1

Entity Wide Disclosures - Additional Information (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
U.S. \| Service Revenue, Net \| Geographical Locations
Product And Services Information [Line Items]
Percentage of service revenue to consolidated service revenue	98.00%	98.00%

Entity Wide Disclosures - Summary of Property and Equipment, Net by Geographic Region (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property and equipment, net:
Property and equipment, net	$ 48,739	$ 43,805
U.S.
Property and equipment, net:
Property and equipment, net	37,535	34,817
Europe [Member]
Property and equipment, net:
Property and equipment, net	9,266	7,436
Other
Property and equipment, net:
Property and equipment, net	$ 1,938	$ 1,552

Quarterly Financial Data (Unaudited) - Schedule of Unaudited Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Service revenue, net	$ 99,448	$ 98,681	$ 94,552	$ 93,781	$ 95,376	$ 94,812	$ 92,633	$ 87,800	$ 386,462	$ 370,621	$ 320,101
Direct costs, excluding depreciation and amortization	55,569	53,144	51,955	51,105	51,074	51,221	49,234	46,981	211,773	198,510	163,707
Income (loss) from operations	15,437	17,198	16,279	15,944	12,890	12,617	14,114	12,869	64,858	52,490	20,562
Net income (loss)	$ 11,291	$ 9,831	$ 9,553	$ 8,447	$ (21)	$ 5,036	$ 4,962	$ 3,448	$ 39,122	$ 13,425	$ (8,673)
Net income (loss) per common share—Basic	$ 0.30	$ 0.25	$ 0.24	$ 0.21	$ 0.00	$ 0.14	$ 0.15	$ 0.11	$ 1.00	$ 0.38	$ (0.28)
Net income (loss) per common share—Diluted	$ 0.30	$ 0.25	$ 0.23	$ 0.20	$ 0.00	$ 0.13	$ 0.15	$ 0.11	$ 0.98	$ 0.37	$ (0.28)